WO2006059712A1 - ヒトステロイドサルファターゼに結合するモノクローナル抗体 - Google Patents
ヒトステロイドサルファターゼに結合するモノクローナル抗体 Download PDFInfo
- Publication number
- WO2006059712A1 WO2006059712A1 PCT/JP2005/022169 JP2005022169W WO2006059712A1 WO 2006059712 A1 WO2006059712 A1 WO 2006059712A1 JP 2005022169 W JP2005022169 W JP 2005022169W WO 2006059712 A1 WO2006059712 A1 WO 2006059712A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- sts
- human
- human sts
- disease
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
Definitions
- the present invention relates to an antibody that specifically binds to human steroid sulfatase (hereinafter abbreviated as STS) and does not bind to arylsulfatase other than human STS (hereinafter abbreviated as ARS).
- STS human steroid sulfatase
- ARS arylsulfatase other than human STS
- the present invention relates to an antibody fragment and a hybridoma that produces the antibody.
- the present invention provides an immunological detection method or immunological quantification method for human STS, an immunological detection reagent or kit for human STS, and an immunological quantification reagent or kit using the antibody or antibody fragment, Furthermore, immunological detection of human STS using the antibody or antibody fragment for determination of human STS-related diseases, selection of drugs suitable for treatment of human STS-related diseases, and determination of the pathology of human STS-related diseases Method or immunological quantification method, reagent or kit for immunological detection of human STS, and reagent or kit for immunological quantification
- Steroid sulfatase (E.C.3.1.6.2.) Is an enzyme that desulfates 3 ⁇ steroid sulfate.
- the conversion of cholesterol sulfate to cholesterol is essential for normal exfoliation of the stratum corneum in the upper epidermis, and the congenital defect of STS causes ichthyosis (Non-patent Document 1).
- STS catalyzes the conversion of estrone precursors such as estrone sulfate to estrone in vivo (Non-patent Document 2).
- the resulting estrone is further converted to estradiol, which is a dehydrogenase-activating hormone.
- Estradiol is a kind of estrogen.
- Some breast, ovarian and uterine cancers are hormone-dependent tumors in which estrogen is deeply involved in their development and proliferation.
- the ratio of estrogen ⁇ estrone sulfate or the enzyme activity of STS is significantly higher in breast cancer and cadaver cancer tissues than in normal yarn and tissue (Non-patent Document 3, Non-Patent Document 4).
- STS in hormone-dependent tumors may be upregulated at the protein level by analysis using antibodies against STS.
- Non-patent Document 5 By immunohistochemical staining using an anti-human STS monoclonal antibody, It is known that the expression of STS is enhanced as compared with normal tissues (Non-patent Document 5). In addition, as a result of immunohistochemical staining of the cancerous part of 113 patients with invasive ductal carcinoma using anti-human STS monoclonal antibody, 74.3% were STS positive, and the expression of STS was tumor size, It showed a positive correlation with recurrence risk and poor prognosis (Non-patent Document 6).
- Breast cancer can be broadly classified into breast cancer, lobular cancer, and Paget's disease, depending on the site of occurrence.
- Non-patent Document 8 Cancers that are only in the breast ducts are called non-invasive cancers, and those that infiltrate the stroma are called invasive cancers. There is a trend. The existence of STS activity has been confirmed in epithelial cancer cells (Non-patent Document 8).
- Endometriosis is a tumor-like benign disease in which tissues similar to the endometrium are ectopically located outside the uterine lumen. Since the eclampsia is proliferated by estrogen, in endometriosis it is increased by estrogen. Uterine adenomyosis is a subtype of endometriosis, in which the eclamptic intima penetrates into the eclampsia layer. Of the 21 patients with eclampsia, 78% of the adenomyosarcoma showed STS expression, and STS expression was restricted to glandular epithelial cells (Non-patent Document 7).
- Non-patent Document 4 As a method for examining the expression of STS, a method for measuring enzyme activity (Non-patent Document 4), a method for quantifying mRNA amount (Non-Patent Document 9), or a detection method and a quantifying method using an antibody (Non-patent Document 4) References 5 and 6) are known.
- STS is a protein belonging to the ARS family. To date, six types of ARS A, B, C, D, E, and F are known, and human STS is the same protein as ARS C.
- Non-Patent Document 2 Endocrinology, 90, 390 (1972)
- Non-Patent Document 3 J. steroid Biochem., 33, 1049 (1989)
- Non-Patent Document 4 Asia- Oceania, J. Obstet. Gynaecol, 15, 101 (1989)
- Non-Patent Document 5 Breast Cancer, 6, 331 (1999)
- Non-Patent Document 6 Cancer Research, 63, 276 (2003)
- Non-Patent Document 7 Obstetrics & Gynecology, 98, 815 (2001)
- Non-patent literature 8 Journal of Clinical Endocrinology & Metabolism, 65, 164 (1987)
- Non-patent literature 9 Cancer Research, 59, 377 (1999)
- Non-Patent Document 10 Cell, 49, 443 (1987)
- An object of the present invention is to provide an antibody or antibody fragment that specifically binds to human STS and does not bind to ARS other than human STS, and a hybridoma that produces the antibody.
- an object of the present invention is to provide an immunological detection method or immunological quantification method of human STS, a reagent or kit for immunological detection of human STS, and an immunological quantification reagent using the antibody or antibody fragment.
- a kit and further, human STS-related diseases using the antibody or antibody fragment for determining human STS-related diseases, selecting drugs suitable for the treatment of human STS-related diseases, and determining the pathology of human STS-related diseases. It is intended to provide an immunological detection method or immunological quantification method, a reagent or kit for immunological detection of human STS, and a reagent or kit for immunological quantification.
- the present invention relates to the following (1) to (53).
- STS human steroid sulfatase
- the antibody or antibody fragment according to (1) which is arylsulfatase other than human STS, arylsulfatase, arylsulfatase, arylsulfatase 0, arylsulfatase E, or arylsulfatase F.
- a human STS-related disease is determined by immunologically detecting or quantifying human STS in a sample using the antibody or antibody fragment of any one of (1) to (5) A method for immunological detection or immunological quantification of human STS in a specimen.
- human STS in a sample is immunologically detected or quantified, and a human STS-related disease is detected from the detection or quantification result.
- human STS in a specimen is immunologically detected or quantified, and a human STS-related disease is detected from the detection or quantification result.
- a method for immunological detection or immunological quantification of human STS for determining the pathological condition of a human is a method for immunological detection or immunological quantification of human STS for determining the pathological condition of a human.
- a reagent or kit for immunological detection of human STS in a specimen characterized in that it comprises the antibody or antibody fragment according to any one of (1) to (5).
- a reagent or kit for immunological quantification of human STS in a specimen characterized in that it comprises the antibody or antibody fragment according to any one of (1) to (5).
- a reagent or kit for determining a human STS-related disease comprising the antibody or antibody fragment according to any one of (1) to (5).
- a reagent or kit for drug selection suitable for treatment of human STS-related diseases characterized by comprising any one of (1) to (5).
- Human STS-related disease is an estrogen-dependent disease involving human STS (29) A reagent or kit according to 1.
- a reagent or kit for determining a disease state of a human STS-related disease comprising the antibody or antibody fragment according to any one of (1) to (5).
- a diagnostic agent for human STS-related diseases comprising the antibody or antibody fragment according to any one of (1) to (5).
- a diagnostic agent for a disease state of a human STS-related disease characterized by comprising any one of (1) to (5).
- the method according to (42), wherein the human STS-related disease is an estrogen-dependent disease involving human STS.
- the estrogen-dependent disease involving human STS is a disease selected from a malignant tumor, a benign tumor, and a skin disease.
- the hyperpridoma according to (6) or (7) is cultured in a medium, and the monoclonal antibody or antibody fragment according to any one of (3) to (5) is produced and accumulated in the culture.
- FIG. 1 shows a Coomassie brilliant-stained image of SDS-polyacrylamide electrophoresis of human STS, which also purified human placental force used as an antigen.
- the left lane shows human STS with purified human placental force, and the right lane shows molecular weight markers. Purified human STS is indicated by an arrow
- FIG. 2 shows the reactivity of monoclonal antibodies to human placenta-derived purified human STS in a binding ELISA.
- the left and right columns show the reactivity with anti-human STS monoclonal antibody KM1049 and anti-human STS monoclonal antibody KM1053, respectively.
- the vertical axis shows the absorbance at 415 nm.
- the black columns show the results when human STS purified from human placenta as an antigen, and the white columns show the results when BSA is immobilized.
- FIG. 3 shows the reactivity of anti-human STS monoclonal antibody KM1049 and anti-human STS monoclonal antibody KM1053 in Western blotting with purified human STS derived from human placenta and human STS expressing E. coli. Indicated. Lane 1 shows human STS expressed in E. coli, and lane 2 shows purified human STS derived from human placenta.
- FIG. 4 shows the ARS activity of human STS gene-introduced cells.
- the vertical axis shows the enzyme activity per unit protein mass.
- CDNA3-1 indicates the activity of a control cell into which a plasmid containing no human STS gene is introduced, and cs3-l indicates the activity of a cell into which a human STS gene is introduced.
- FIG. 5 shows the reactivity of the monoclonal antibody by immunoprecipitation with human STS derived from cs3-l cells into which human STS gene has been introduced.
- Lane 1 shows the result of immunoprecipitation with the negative control monoclonal antibody KM1063, Lane 2 with the anti-human STS monoclonal antibody KM1053, and Lane 3 with the anti-human STS monoclonal antibody KM1049.
- FIG. 6 shows the reactivity of monoclonal antibodies and human STS gene-introduced cells by immunocytostaining (flow cytometry).
- the white chromatogram shows the results when using the monoclonal antibody KM1063 as a negative control
- the black chromatogram shows the results when using the anti-human STS monoclonal antibody KM1053.
- A shows the result in the control cell CDNA3-1 cell into which the plasmid was introduced
- B contains the human STS gene
- B shows the result in the cell cs3-l cell into which the human STS gene was introduced.
- FIG. 7 shows the ARS activity of various ARS gene-introduced cells.
- the vertical axis is Shows ARS activity per cell.
- the ARS activity of the cells is shown by introducing the negative control various ARS genes, and the right column shows the ARS activity of the cells introduced by the various ARS genes.
- a ⁇ is ARS A transgenic cell, B ⁇ is ARS B transgenic cell, C ⁇ is ARS D transgenic cell, D ⁇ is ARS E transgenic cell, E is ARS F The result of a transgenic cell is shown.
- FIG. 8 shows the reactivity of monoclonal antibody KM1049 with ARS derived from various ARS gene-introduced cells in Western blotting.
- Lane 1 shows ARS A
- Lane 2 shows ARS B
- Lane 3 and ARS C Lane 4 and ARS D
- Lane 5 and ARS E Lane 6 and ARS F, respectively.
- FIG. 9 shows the reactivity of the anti-human STS monoclonal antibody KM1053 with various ARS gene-introduced human STSs in immunoprecipitation.
- Lane 1 is ARS A
- Lane 2 is ARS B
- Lane 3 is ARS C
- Lane 4 is ARS D
- Lane 5 is ARS E
- Lane 6 is ARS F.
- FIG. 10 shows the reactivity of anti-human STS monoclonal antibody KM1049 and anti-human STS monoclonal antibody KM1053 with various ARSs in binding ELISA.
- A shows the results using anti-human STS monoclonal antibody KM1049
- B shows the results using anti-human STS monoclonal antibody KM1053.
- the vertical axis indicates the absorbance at 415 °
- the horizontal axis indicates the antibody concentration.
- ⁇ indicates animal cell expression purified ARS C
- broken line ⁇ indicates ARS A
- country indicates ARS B.
- FIG. 11 shows a calibration curve of purified animal cell-derived human ST S by sandwich ELISA using anti-human STS monoclonal antibody KM1053 and piotinized anti-human STS monoclonal antibody KM1049.
- the horizontal axis represents protein concentration, and the vertical axis represents 415 absorbance.
- ⁇ indicates animal cell expression purified human STS, and broken line ⁇ indicates recombinant purified IL-1 ⁇ which is a negative control.
- the present invention relates to an antibody that specifically binds to human STS and does not bind to ARS other than human STS.
- ARS other than human STS examples include ARS A, B, D, E and F.
- Human of the present invention examples of antibodies that specifically bind to STS but do not bind to ARS other than human STS include antibodies that specifically bind to human STS (AR SC) and do not bind to A, B, D, E, and F of ARS. Can be raised.
- Examples of the antibody of the present invention include polyclonal antibodies and monoclonal antibodies, and preferably include monoclonal antibodies.
- polyclonal antibodies include antisera from immunized animals or polyclonal antibodies purified from the antisera.
- the polyclonal antibody of the present invention includes any antibody that specifically binds to human STS and does not exhibit cross-reactivity with ARS other than STS.
- a human STS was immunized with the animal's sera, and the animal's serum was collected, and the fractions reactive to ARS A, B, D, E, and F, which are ARS other than human STS, were removed.
- polyclonal antibodies prepared by known affinity purification methods examples of mammals other than humans include mouse, rat, nomstar, guinea pig, rabbit, goat, horse, mouse, sheep, goat, pig, and chicken.
- Monoclonal antibodies may include antibodies or antibody fragments produced by wild or hybridoma, or recombinant antibodies or antibody fragments produced by a transformant transformed with an expression vector containing an antibody gene. .
- Hypridoma cell line KM1053 As a specific example of the monoclonal antibody of the present invention, anti-human STS monoclonal antibody KM1053 produced by Hypridoma cell line KM1053 can be mentioned.
- Hypridoma cell line KM1053 was established on April 27, 2004 in accordance with the Budapest Treaty. National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center (Tsukuba Nadahigashi, 1-chome, 1-chome, Ibaraki, Japan) Deposited as BP-10015.
- the monoclonal antibody of the present invention includes the above-described hyperidoma cell line KM1053.
- monoclonal antibodies that bind to the same epitope to which the monoclonal antibody produced by (FERM BP-10015) binds.
- a gene recombinant antibody is obtained by modifying the above-described monoclonal antibody of the present invention using gene recombination technology.
- the recombinant antibody include human chimeric antibodies, humanized antibodies, human antibodies or antibody fragments such as antibodies produced by genetic recombination.
- the recombinant antibody of the present invention include antibodies that retain the characteristics of a monoclonal antibody in the recombinant antibody.
- the human chimeric antibody is an antibody heavy chain (hereinafter referred to as H chain) V region (hereinafter, antibody heavy chain variable region is referred to as VH) of an antibody of a non-human animal, and an antibody light chain.
- V region hereinafter referred to as L chain
- V region hereinafter referred to as antibody variable region light chain VL
- CH human antibody heavy chain constant region
- CH human antibody light chain constant region
- the human chimeric antibody of the present invention obtains cDNA encoding VH and VL from the hyperprideoma producing the monoclonal antibody of the present invention, and has genes encoding human antibody CH and human antibody CL.
- a human chimeric antibody expression vector inserted into an animal cell expression vector can be constructed and introduced into animal cells for expression and production.
- the structure of the human chimeric antibody of the present invention may belong to any immunoglobulin (Ig) class, but it may be an IgG type, or an IgGl, IgG2, IgG3, or IgG4 immunoglobulin belonging to the IgG type. C region is preferred.
- the humanized antibody is also called a human complementarity determining region (hereinafter referred to as CDR) transplanted antibody or a reshaped antibody.
- CDR human complementarity determining region
- the humanized antibody was constructed by constructing a gene encoding the V region obtained by substituting the VH and VL CDR sequences of any human antibody with the VH and VL CDR sequences of the monoclonal antibody of the present invention. It can be produced from cocoons by introducing it into an expression vector for animal cells having a gene encoding CL of human antibody and expressing it.
- the structure of the C region of the humanized antibody of the present invention may be V, or may belong to the immortal immunoglobulin (Ig) class, but may be an IgG type, or an IgGl, IgG2, IgG3,
- the immunoglobulin C region, such as IgG4, is preferred.
- a human antibody originally means an antibody naturally present in the human body, but a human antibody phage library produced by recent advances in genetic, cell engineering, and developmental technology, and a human antibody Includes production of transgenic animal strength antibodies
- Antibodies present in the human body for example, isolated human peripheral blood lymphocytes that produce human antibodies
- the lymphocytes that produce the antibody can be cultured as antibody-regenerating cells by immortalizing and single-cloning by infecting with EB virus or the like, and the antibody can be purified from the culture. Can do.
- the human antibody phage library is a library in which antibody fragments prepared from human antibody-producing cells such as B cells or lymphocytes are inserted into phage vectors to express antibody fragments such as Fab and scFv on the phage surface. I mean. From the library, phages expressing antibody fragments having a desired antigen-binding activity can be recovered using the binding activity to the substrate on which the antigen is immobilized as an index. The antibody fragment can be further converted into a human antibody molecule having two complete heavy chains and two complete light chains using genetic engineering techniques.
- a human antibody-producing transgenic animal means an animal in which a human antibody gene is integrated in the genome.
- a human antibody-producing transgenic animal can be created by introducing a human antibody gene into a mouse ES cell, transplanting the ES cell to another mouse early embryo, and generating it.
- Human antibody-producing transgenic animal-powered human antibodies can be produced from the culture by obtaining and culturing human antibody-producing hyperpridoma using conventional methods for producing hyperidoma in mammals other than humans. The antibody can be purified.
- Examples of the antibody fragment of the present invention include an antibody fragment obtained by digesting an antibody with an appropriate peptidase or an antibody fragment produced by gene recombination.
- Antibody fragments include Fab (Fragment of antigen binding, Fab, F, ab 2, single chain antibody (hereinafter referred to as scFv) [Science, 242, 423 (1988)], dimer Variable region (also called Diabody) [Natur e BiotechnoL, 15, 629 (1997)], and disulfide stabilized V region fragment (hereinafter referred to as dsFv) [Molecular Immunol, 32, 249 (1995)
- peptides containing the amino acid sequences of CDRs of the above VH and VL hereinafter referred to as peptides containing CDRs
- Fab is an N-terminal half of the H chain obtained by cleaving the peptide part at the top of the two disulfide bonds that bridge the two H chains at the hinge region of IgG with the enzyme papain, and the L chain. It is an antibody fragment having an antigen binding activity with a molecular weight of about 30,000 composed of the whole.
- the Fab of the present invention can be obtained by treating the monoclonal antibody of the present invention with the enzyme nopain.
- a Fab is produced by inserting a DNA encoding the Fab fragment of the antibody into a prokaryotic expression vector or a eukaryotic expression vector, and expressing the vector by introducing the vector into a prokaryotic or eukaryotic organism. Can do.
- Fab ' is an antibody fragment having an antigen binding activity of about 50,000 molecular weight obtained by cleaving the disulfide bond between the hinges of F (ab') 2 described below.
- the Fa of the present invention can be obtained by treating the monoclonal antibody F (a) 2 of the present invention with a reducing agent dithiothreitol.
- a DNA encoding the Fa fragment of the antibody is inserted into a prokaryotic expression vector or a eukaryotic expression vector, and the vector is expressed by introducing it into a prokaryotic or eukaryotic organism to produce Fab ′.
- F (ab ') 2 is obtained by treating the lower part of two pairs of disulfide bonds in the hinge region of IgG with the enzyme trypsin. It is an antibody fragment having the antigen binding activity.
- F (ab ′) 2 of the present invention can be obtained by treating the monoclonal antibody of the present invention with a reducing agent dithiothreitol. Alternatively, by inserting the DNA encoding the F (ab ′) 2 fragment of the antibody into a prokaryotic expression vector or eukaryotic expression vector, and introducing the vector into a eukaryotic organism. It can be expressed to produce F (ab ′) 2.
- scFv is a VH-P-VL or VL-P-VH polypeptide in which one VH and one VL are linked using an appropriate peptide linker (hereinafter referred to as P). Indicated.
- P peptide linker
- the scFV of the present invention obtains cDNA of VH and VL from the monoclonal antibody of the present invention, inserts the DNA encoding the scFv fragment of the antibody into a prokaryotic expression vector or eukaryotic expression vector, Can be expressed by introducing it into prokaryotes or eukaryotes to produce scFv.
- Diabody is an antibody fragment in which scFv with the same or different antigen-binding specificity forms a dimer, an antibody having a bivalent antigen-binding activity against the same antigen or a bispecific antigen-binding activity against different antigens It is a fragment.
- the diabody of the present invention obtains cDNA of VH and VL from the monoclonal antibody of the present invention, inserts the DNA encoding the diabody fragment of the antibody into a prokaryotic expression vector, or inserts the DNA into a eukaryotic expression vector. Can be expressed by introducing it into prokaryotes or eukaryotes to produce diabody.
- dsFv is obtained by binding a polypeptide in which one amino acid residue in each of VH and VL is replaced with a cysteine residue by a disulfide bond.
- the amino acid residue to be substituted with the cysteine residue can be selected based on the three-dimensional structure prediction of the antibody according to the method shown by Reiter et al. [Protein Engineering, 7, 697 (1994)]. Any of the monoclonal antibodies of the present invention can be used as VH and VL contained in the dsFv of the present invention.
- dsFv of the present invention cDNA of VH and VL is obtained from the monoclonal antibody of the present invention, and a DNA encoding the dsFv fragment of the antibody is inserted into a prokaryotic expression vector or a eukaryotic expression vector.
- the dsFv can be produced by expressing the vector by introducing it into a prokaryotic or eukaryotic organism.
- the peptide containing CDR is composed of at least one region of CDR of VH or VL.
- a peptide containing a plurality of CDRs can be produced by binding directly or via an appropriate peptide linker.
- the VH molecule and VL molecule were synthesized from mRNA prepared from the hybridoma producing the monoclonal antibody of the present invention, and the gene fragment containing VH or VL was cloned by a method such as PCR. It can be produced by expressing in an appropriate combination of expression vector and host. In order to obtain a molecule due to its affinity with the human STS molecule, it can be said that the expression vector is a phage expression vector and the host is E. coli. It is expressed by expressing and producing a VH molecule and a VL molecule as a fusion protein with a desired protein.
- Peptides containing the CDR of the present invention are obtained from the monoclonal antibody of the present invention from VH and V Expression is obtained by obtaining cDNA from L, inserting DNA encoding the peptide containing the CDR of the antibody into a prokaryotic expression vector or eukaryotic expression vector, and introducing the vector into prokaryotic or eukaryotic organisms.
- a peptide containing CDR can be produced.
- a peptide containing CDR can also be produced by a chemical synthesis method such as Fmoc method (fluoromethyloxycarbol method) or tBoc method (t_ptyoxycarboxyl method).
- the monoclonal antibody or antibody fragment of the present invention comprises a derivative of an antibody in which a radioisotope, protein, drug, or the like is introduced or bound to the antibody or antibody fragment either chemically or genetically. Include.
- the derivative of the antibody of the present invention includes the N chain side or the C terminal side of the H chain or L chain of the monoclonal antibody or antibody fragment of the present invention, and further appropriate substituents or side chains in the antibody or antibody fragment. Furthermore, it can be produced by chemically binding a radioisotope, protein, or drug to a sugar chain in an antibody or antibody fragment [Introduction to antibody engineering, Osamu Kimemitsu, Jinjinshokan Co., Ltd. (1994)].
- the DNA encoding the anti-human STS antibody or antibody fragment and the DNA linked to the protein encoding the ligated DNA are inserted into a prokaryotic expression vector or eukaryotic expression vector, and the vector is inserted. It can be expressed and genetically engineered by introduction into prokaryotic or eukaryotic organisms.
- the drug may be any substance such as a radioisotope, protein, or small molecule.
- Examples of the drug when the derivative of the antibody of the present invention is used as a detection method, a quantification method, a detection reagent, a quantification reagent or a diagnostic agent include labels used in usual immunoassay methods.
- Labels include radioisotopes, enzymes such as alkaline phosphatase, peroxidase and luciferase, luminescent substances such as attalidum esters, mouth fins, fluorescein isothiocyanate (FITC), rhodamine isothiocyanate (HRIT C), etc. And fluorescent materials.
- substances such as piotin can be used as a label as a drug.
- the substance is bound with a radioactive isotope, an enzyme such as alkaline phosphatase, peroxidase, or luciferase, a luminescent substance such as ataridum ester or loffin, or a fluorescent substance such as FITC or RITC, such as avidin.
- a radioactive isotope an enzyme such as alkaline phosphatase, peroxidase, or luciferase, a luminescent substance such as ataridum ester or loffin, or a fluorescent substance such as FITC or RITC, such as avidin.
- Secondary labeling substances that can bind to the substance with specific and high affinity can be used It is a substance to be damped.
- the present invention also relates to an immunological detection method or immunological quantification method for human STS in a specimen using the antibody or antibody fragment of the present invention described above.
- Immunological detection methods or immunological quantification methods include fluorescent antibody methods, immunoenzyme antibody methods (ELISA), immunological assay methods such as radioactive substance-labeled immunoantibody method (RIA), immune cell staining methods, immunological methods.
- Immunochemical staining methods such as tissue staining method, Western blotting method, dot blotting method, immunoprecipitation method [Monoclonal antibody experiment manual, Kodansha Scientific (1987), secondary biochemistry experiment course 5 Immunobiochemical research method, Tokyo Chemical Doujin (1986)].
- Examples of the immunological measurement method include any known immunological measurement method.
- immunoassays depend on the labeling method, depending on the radioimmunoassay (RIA), enzyme immunoassay (EIA or ELISA), fluorescence immunoassay (FIA), luminescence immunoassay (luminescent) immunoassay), physicochemical detection methods (TIA, LAPIA, PCIA) and the like, preferably enzyme immunoassay methods.
- RIA radioimmunoassay
- EIA or ELISA enzyme immunoassay
- FIA fluorescence immunoassay
- FIA fluorescence immunoassay
- luminescence immunoassay luminescence immunoassay
- physicochemical detection methods TIA, LAPIA, PCIA
- enzyme immunoassay methods preferably enzyme immunoassay methods.
- any known enzyme edited by Yuji Ishikawa et al., Enzyme Immunoassay, Medical School
- any known enzyme edited by Yuji Ishikawa et al., Enzyme Immunoassay, Medical School
- alkaline phosphatase, peroxidase, luciferase and the like can be used.
- any known luminescent substance [Imai Kazuhiro, Bioluminescence and Chemiluminescence, Yodogawa Shoten; Clinical Laboratory 42 (1998)] can be used.
- ataridium and its derivatives, ruthenium complex compounds, mouth fins and the like can be used.
- ruthenium complex compound for example, those described in Clin. Chem. 37, 1534 (1991) are preferable.
- the compound emits electrochemically with an electron donor
- any known fluorescent material (Akira Kawao, fluorescent antibody method, manufactured by Soft Science) can be used.
- FITC, RITC, etc. can be used.
- other fluorescent materials include quantum dot [Science, 281, 2016 (1998)].
- a phycopyriprotein such as phycoerythrin, GFP (Green fluorescent Protein)! / ⁇ may be a fluorescent protein such as its related protein.
- the immunological measurement method is a method of measuring the amount of antibody or the amount of antigen using the above-described various labeled antigens or antibodies.
- the immunological assay of the present invention may be any method as long as it is a method for detecting or measuring an antigen.
- the competitive method and the sandwich method [Immunology Illustrated 5th edition, Nankodo] are mentioned, but the sandwich method is preferable.
- the sandwich method is a method in which a first antibody is bound to a solid phase, an antigen to be measured is trapped, and a labeled second antibody is reacted.
- an antibody to be used in the sandwich method antibody fragments such as Fab, Fab ′, and F (ab) 2 described above, which may be either polyclonal antibodies or monoclonal antibodies, may be used.
- the combination of the two types of antibodies used in the sandwich method may be a combination of antibodies or antibody fragments that recognize different epitopes! /, Or a combination of polyclonal and monoclonal antibodies or antibody fragments.
- Specific examples include a combination of anti-human STS monoclonal antibody KM1053, which is an example of the monoclonal antibody of the present invention, and known anti-human STS monoclonal antibody KM104 9 [Cancer Research, 63, 2762 (2003)].
- the fluorescent antibody method is a method in which a sample considered to contain human STS is reacted with the antibody or antibody fragment of the present invention and further labeled with a fluorescent substance such as FITC, or an anti-mouse immunoglobulin (Ig) antibody or Immunoglobulin G (IgG) antibody! / ⁇ is a method in which fluorescent fragments are measured by flow cytometry or fluorescence microscope after reacting antibody fragments.
- a derivative in which the antibody or antibody fragment of the present invention is directly labeled with a fluorescent substance can also be used.
- a derivative labeled with the antibody or antibody fragment with piotin or the like is reacted and then or At the same time, after reacting a secondary labeling substance labeled with a fluorescent substance, the fluorescent dye may be measured by flow cytometry or a fluorescence microscope.
- a luminescent substance such as an atelidum ester or a mouth fin instead of the fluorescent substance.
- a luminescence measuring instrument can be used as the measuring instrument.
- the immunoenzyme antibody method is to react a sample considered to contain human STS with the antibody or antibody fragment of the present invention, and further with an anti-mouse Ig antibody or IgG antibody or antibody fragment to which an enzyme label such as peroxidase is applied. After the enzyme substrate is colored as a result of the enzyme reaction If it is a substance that produces the drug substance, the dye color reaction is measured with an absorptiometer. In this method, a derivative obtained by directly labeling the antibody or antibody fragment of the present invention with an enzyme can be used, and a derivative labeled with the antibody or antibody fragment is reacted with piotin or the like, and then or simultaneously. A method of measuring a dye color reaction with an absorptiometer after reacting with a secondary labeling substance labeled with an enzyme may be used.
- the luminescence can also be measured with a luminescence measuring device.
- the compound exhibiting chemiluminescence by an enzyme include peroxidase substrates such as luminol compounds and lucigen compounds. Or as a substrate for alkaline phosphatase, for example, 3-(2 — aaamantyl) — 4— methoxy— 4— (3 '-phosphoryloxy) pheny ⁇ 1,2— dioxetane, a phosphate derivative of agridi-um APS2, APS3, APS5, etc. [Lumigen Inc. Luminescent Compound, H.
- luciferin Alternatively, luciferin, coelenterazine and the like are listed as luciferase substrates.
- Radioactive-labeled immunoantibody method refers to an anti-mouse Ig antibody or a radiolabeled anti-mouse Ig antibody or antibody fragment reacted with a specimen considered to contain human STS.
- IgG antibody is a method in which antibody fragments are reacted and then measured with a scintillation counter or the like.
- a derivative obtained by directly labeling the antibody or antibody fragment of the present invention with a radioactive substance can be used, and the derivative labeled with the antibody or antibody fragment is reacted with piotin or the like, and then or simultaneously.
- a method may be used in which a secondary labeling substance labeled with a radioactive substance is reacted and then measured with a scintillation counter or the like.
- the immunochemical staining method includes human STS or a microorganism or animal cell expressing human STS! /, Or an insect cell reacted with the antibody of the present invention, and further, a fluorescent substance such as FITC, peroxidase, or piotin.
- the antibody of the present invention to which an enzyme label such as the above is applied is a method in which an antibody fragment is reacted and then observed using a microscope or flow cytometry.
- the immune cell staining method can be used to detect the antibody of the present invention or cultured cells derived from force-collected cells or microbes such as human or animal living tissues, human or animal or insects, and the like. Is a method for analyzing the expression of human STS after binding antibody fragments and using techniques such as flow cytometry to analyze the amount or state of antibody binding in a single cell.
- the immune cell staining method the above-mentioned cells are directly fixed on a slide glass or cultured on a slide glass, and then the antibody or antibody fragment of the present invention is reacted, and then the expression of human STS contained in the cells is observed with a microscope. Alternatively, a method of observing or quantifying using a camera or the like is also included.
- a clot is prepared with agarose or the like, and then the clot is frozen or wrapped in paraffin. It is a method of burying, slicing the tissue piece into sections, fixing the sections to glass or other glass slides, and observing or quantifying the expression of human STS using a microscope or a camera by the same procedure as above.
- a tissue piece collected from a human or animal body tissue is fixed or fixed with a fixative such as formalin or ethanol, and the tissue piece is fixed.
- a fixative such as formalin or ethanol
- Frozen or embedded in paraffin prepared a tissue section from the tissue piece, fixed the tissue section on a glass slide such as glass, removed unwanted substances such as deparaffin, and further with antigen as needed
- the expression of human STS contained in the tissue section is observed or quantified using a microscope or a camera. is there.
- an immunostaining method using a fluorescent substance, a luminescent substance, an enzyme, and a radioactive substance-labeled antibody is possible, and the above-described immunological measurement method suitable for each label and Detection or measurement can be performed by a similar procedure.
- Western blotting refers to human STS or cell extracts of human STS-expressing microorganisms, animal cells, or insect cells.
- SDS-polyacrylamide gel electrophoresis [Antioodies-A Laboratory Manual, Cold bpnng Haroor Laboratory ( 1988)]
- the fractionated protein group is blotted onto a PVDF membrane or a -trocellulose membrane by Gelka et al.
- the antibody or antibody fragment of the present invention is allowed to react with the membrane.
- This is a method for confirming after reacting a secondary antibody antibody or antibody fragment that is capable of binding to the antibody of the present invention, which is labeled with an enzyme such as a fluorescent substance, peroxidase, or piotin.
- the dot blotting method refers to human STS or microorganisms or animal cells expressing human STS.
- a cell extract of insect cells is blotted onto a trocellulose membrane, and the antibody of the present invention is reacted with the membrane, followed by enzyme labeling such as a fluorescent substance such as FITC, peroxidase, biotin, etc. This is a method of confirming after reacting a secondary antibody antibody or antibody fragment capable of binding to the antibody of the invention.
- the immunoprecipitation method is a method in which a human STS or a cell extract of a microorganism, animal cell, or insect cell expressing human STS is reacted with the antibody or antibody fragment of the present invention, followed by protein G-sepharose or the like. This is a method of precipitating an antigen-antibody complex by covering a carrier having a specific binding ability to munoglobulin.
- the antibody of the present invention can be prepared, for example, as follows.
- An expression vector containing cDNA encoding human STS is introduced into Escherichia coli, yeast, insect cells, animal cells, etc. to obtain recombinant human STS.
- a fusion protein in which a tag protein is fused to the C-terminus or N-terminus of a recombinant protein that is an immunogen can also be used as an immunogen.
- the term “tag protein” means that the target protein is excessively added to the end of the desired protein for the purpose of easily separating the protein by affinity purification or for tracking the behavior of the target protein. A protein to be added.
- tag proteins examples include dartathione-S-transferase (GST), protein A, j8-galactosidase, maltose-binding protein (MBP), and the like.
- GST dartathione-S-transferase
- MBP maltose-binding protein
- human STS can be purified from human thread and tissue expressing a large amount of STS such as placenta and used as an antigen.
- a synthetic peptide having a human STS partial sequence can also be used as an antigen.
- human STS is purified from human placental tissue as follows. All operations are performed at 4 ° C.
- placental tissue homogenate is prepared in buffer A [0.25 mmol / L saccharose, 5 mmol / L EDTA, 10 mmol / L Tris-acetate buffer (pHLO)] after shredding.
- buffer A 0.5 mmol / L saccharose, 5 mmol / L EDTA, 10 mmol / L Tris-acetate buffer (pHLO)
- the obtained microsomal fraction is buffer B [lmmol / L LOmmol / L Tris-HCl buffer (pH7.) Containing EDTA, lmmol / L Dithioerythreitol (DTE), 0.05% phenylmethansulfonylfluoride (PMSF), 0.5% Triton X-100 5)] is added and stirred at room temperature for 1 hour to dissolve. Centrifuge at 105000 Xg for 1 hour to remove insoluble fraction.
- the obtained supernatant was passed through a PBE94 column equilibrated with Buffer B (pH 8.0), washed with 2 volumes of the same buffer, and then Coffer C [lmmol / L EDTA, lmmol / L DTE , 0.05% PMSF, 0.5% Triton X- 100, eluting with 12. 5% polybuffer 7 4 (pH4.0 )]. Further, the eluted fraction was passed through a phase-sepharose column equilibrated with buffer B, washed with a sufficient amount of the same buffer, and then eluted with the same stopper to which 1.25% Triton X-100 was added. Used as purified human STS.
- the human STS obtained in this manner can be used as a standard substance in the detection method or quantification method of human STS, in addition to being used as an antigen when preparing the following antibody-producing cells.
- Immunization involves administering the antigen subcutaneously, intravenously, or intraperitoneally with an appropriate adjuvant (for example, complete Freund's Adjuvant, aluminum hydroxide gel and pertussis vaccine).
- an appropriate adjuvant for example, complete Freund's Adjuvant, aluminum hydroxide gel and pertussis vaccine.
- an appropriate adjuvant for example, complete Freund's Adjuvant, aluminum hydroxide gel and pertussis vaccine.
- an appropriate adjuvant for example, complete Freund's Adjuvant, aluminum hydroxide gel and pertussis vaccine.
- a carrier protein such as ushi serum albumin (hereinafter abbreviated as BSA) or keyhole Limpet hemocyanin (hereinafter abbreviated as KLH) and a conjugate are used. Made and used as an immunogen.
- BSA ushi serum albumin
- KLH keyhole Limpet hemocyanin
- the antigen is administered 5 to 10 times every 1 to 2 weeks after the first administration. Three to seven days after each administration, blood is collected from the fundus venous plexus, and the serum reacts with the antigen (Anti bodies-A Laboratory Manual, Cold bpnng Haroor Laboratory (1988))
- the source of antibody-producing cells is a mouse, rat or hamster whose serum shows a sufficient antibody titer against the antigen used for immunization.
- the spleen is removed from the immunized mouse, rat or hamster 3 to 7 days after the final administration of the antigen, and the spleen cells are collected. To take. The spleen is shredded in MEM medium (Nissui Pharmaceutical Co., Ltd.), loosened with tweezers, centrifuged (1200 rpm, 5 minutes), the supernatant was discarded, and Tris monosalt-ammum buffer ( Treat with pH7.65) for 1-2 minutes to remove erythrocytes, wash 3 times with MEM medium, and provide as antibody-producing cells.
- myeloma cells cell lines obtained from mice are used.
- myeloma cell line P3- X63Ag8- Ul (P3- Ul) myeloma cell line P3- X63Ag8- Ul (P3- Ul) [Current Topics in Microbiology and Immunology, 18, 1 (1978)], P3- NSl / 1 — Ag41 (NS— 1) [Eur opean J. Immunology, 6, 511 (1976)], SP2 / 0-Agl4 (SP-2) [Nature, 276, 269 (19 78)], P3— X63— Ag8653 ( 653) [J.
- This mouse force also collected ascites, centrifuged (3000 rpm, 5 minutes) to remove the solids, salted out with 40-50% ammonium sulfate, force pruric acid precipitation method, DEAE-Sepharose column, Purify using a protein A-column or gel filtration column to obtain IgG or IgM fractions to obtain purified monoclonal antibodies.
- the subclass of the antibody is determined by enzyme immunoassay using a sub-clustering kit.
- the amount of protein is quantified based on the Raleigh method or absorbance at 280 hours.
- antigen purified recombinant human STS, purified human STS or a human STS partial peptide that has obtained strength such as human placenta is used.
- the antigen is a partial peptide
- a conjugate with a carrier protein such as BSA or KLH is prepared and used.
- BSA-PBS PBS solution containing 1% BSA
- Hypidoma culture supernatant of monoclonal antibody or purified antibody 1 ⁇ Dispense 10 ⁇ g / mL in 20-100 ⁇ L / well and leave at room temperature for 2-3 hours or at 4 ° C. After washing thoroughly with PBS or PBS containing 0.05% Tween 20 (hereinafter referred to as Tween-PBS), the antibody was labeled with piotin, enzyme, chemiluminescent substance, or radioactive compound.
- the antibody of the present invention can detect or quantify microorganisms, animal cells, insect cells, and the like expressing human STS or human STS contained in a specimen by using an immunological technique.
- an immunological technique any known immunological measurement method or the like is used.
- the immunological measurement method of the present invention include western blotting, immunoprecipitation, immunocytostaining, immunohistochemical staining, A sandwich ELISA method or the like is preferably used.
- specimens examples include human-derived biological samples, microorganisms considered to express human STS, cells or tissues derived from animals, insects, and the like, and human-derived biological samples are preferable.
- biological samples derived from humans include biological samples collected from human individuals suspected of suffering from diseases related to human STS.
- biological samples include tissues or cells at the disease site, or tissues or cells that are released from the disease site and contained in body fluids such as blood, lymph, peritoneal fluid, milk, eclampsia, urine, and sweat. Is done. further
- the body fluid containing STS released from the tissue or cells is also included.
- Biological samples also include cultured human tumor cells, tissues or cells collected from human individuals suspected of suffering from diseases associated with human STS, and extracts prepared from these tissues or cells. Is done.
- a sample obtained by processing a biological sample collected from these human individuals may also be used as the biological sample. Examples of processing include dilution, concentration, extraction, and pathological section preparation. Examples of the treatment in the preparation of a pathological section include a series of treatments such as formalin fixation, excision, embedding, slicing, and extension.
- the tissue or cell collection method includes fine needle aspiration cytology and needle biopsy (mammotome).
- Surgical biopsy Surgical biopsy, papillary fluid cytology (milk cytology), cell collection with a duct endoscope, etc. can give.
- liquid fractions such as plasma or serum and solid fractions such as cells are separated by centrifugation or filtering. It is desirable to use it afterwards.
- the fractionated liquid fraction and solid fraction can be used as a biological sample.
- the tissue or cells are preferably collected directly from the disease site, but even a biological sample free from disease site can be used as the specimen of the present invention.
- the disease site may be a primary lesion or a metastatic lesion.
- a method for preparing an extract from the above tissues or cells a method in which collected tissues or cells are vigorously stirred together with a liquid, a method in which a cell membrane is destroyed with acid or alkali, a cell membrane in a surfactant is used.
- Examples include a method of destroying tissue or cells and obtaining a cytoplasm by a method of disrupting cells, a method of disrupting with ultrasound, a method of disrupting cells with a hypotonic solution, a method of repeatedly freezing and thawing.
- Detection of human STS by Western blotting using the antibody of the present invention can be carried out as follows.
- culture supernatant of hyperidoma producing monoclonal antibody of the present invention or purified monoclonal antibody of 1-10 / zg / mL of the present invention is allowed to react at room temperature for 2 hours or at 4 ° C. .
- the secondary antibody is piotin, enzyme, chemiluminescent substance or radiation compound. 1 to 50 g / mL of anti-immunoglobulin antibody labeled with the above is allowed to react at room temperature for 1 to 2 hours.
- a reaction corresponding to the labeling substance of the second antibody is performed, and a protein with a molecular weight predicted from the amino acid sequence of human STS is bound to an antibody that specifically binds to human STS and does not bind to ARS other than STS. Confirm that it does not react with antigens that do not contain human STS and ARS other than STS.
- Immunoprecipitation using the antibody of the present invention can be performed by the following method.
- the antibody of the present invention (1 to 10 ⁇ g / reaction) is added to the sample prepared as described above, and reacted at 4 ° C for 1 hour. Further, 5 to 20 L of a carrier having a specific binding ability to immunoglopurin such as protein G-sepharose is added thereto, followed by reaction at 4 ° C for 1 hour, followed by centrifugation to obtain a precipitate fraction. The precipitate fraction is washed several times with a cell extraction buffer and then subjected to Western blotting as an exudate.
- a carrier having a specific binding ability to immunoglopurin such as protein G-sepharose
- the antibody of the present invention is immobilized on a 96-well plate for ELISA and then blocked with BSA-PBS. If the antibody is the culture supernatant of a monoclonal antibody-producing hyperpridoma, the antibody or protein A or protein G that binds to the animal immunoglobulin of the antibody-producing cells used in the preparation of the hyperidoma is used in advance for ELISA. After immobilizing in a well plate and blocking with BSA-PBS, dispense and bind the Hypridoma strain culture supernatant. Discard the BSA-PBS and wash with PBS.
- the sample remaining in each well of the plate after thoroughly washing with cell extraction buffer or Tween-PBS is subjected to the above Western blotting to detect or quantify the immunoprecipitated human STS.
- detection can be performed by immunocytostaining human STS as follows. Togashi.
- the cells For various human tumor cells, wash floating cells with PBS. Adherent cells are washed with trypsin or EDTA and then washed with PBS. Cell souls collected from patients by neuropsy etc. are treated with collagenase and then washed with PBS. These cells are treated with a surfactant or methanol to improve antibody permeability. After blocking with normal human serum or the like, the cells are dispensed in 1 ⁇ 10 5 to 1 ⁇ 10 6 cell Z-tubes to produce the monoclonal antibody of the present invention, the culture supernatant of the hybridoma of the present invention, or the purified monochrome of the present invention. -React with 1 to 10; ⁇ / ⁇ ⁇ for 30 minutes at room temperature.
- human STS can be detected or quantified by immunohistochemical staining as follows.
- Examples of human tissue collection include a method of collecting a tissue containing a target tissue such as a diseased site obtained by surgery or biopsy.
- the collected tissue can be used as a sample as it is.
- a section is prepared by an appropriate method and used for the reaction with the antibody.
- an operation such as antigen activation or endogenous substance blocking reaction may be added.
- a method of preparing a section a method in which it is frozen in an unfixed state and a frozen section is prepared and then fixed, a method in which a frozen section is frozen after fixing and a section in which the sample is fixed and embedded in paraffin or the like and then sectioned is prepared. And the like.
- the method of fixing after freezing and preparing a frozen section is to cut the tissue into small pieces, place in a frozen embedding medium such as OCT compound, and freeze rapidly with dry ice / acetone. After air-drying, a method is used in which a section is prepared and fixed using the following fixative. If the sections are not prepared immediately, they can be air-dried with acetone, sealed, and stored in a deep freezer as a frozen cell mass. [0090] As a method for freezing after fixation and preparing a frozen section, the tissue is minced and then fixed with the following fixative, and washed with, for example, PBS or PBS containing 10 to 20% sucrose.
- the tissue is minced, fixed with the following fixative, dehydrated with ethanol, xylene, etc., and then paraffin embedded.
- a method of preparing a norafine block and preparing a section with a paraffin block force is used. If sections are not prepared immediately, they can be stored as paraffin blocks.
- Examples of the fixing method include immersion fixing, injection fixing, deaeration fixing, freeze replacement fixing, freeze drying fixing, and the like.
- the fixing time is preferably from half a day to one week, but generally from 1 to 2 days is more preferable.
- the fixed time can be shortened to several hours by using a microwave or a household microwave oven.
- a method for preparing a section there is a method using a cryostat in the case of a frozen section, or a method using a microtome in the case of a paraffin section.
- fixative examples include aldehyde-based fixatives that cause cross-linking formation in protein / peptide chains centered on aldehydes, and organic solvent-based fixatives based on protein coagulation precipitation.
- fixatives Revised 4th edition Watanabe / Nakane Enzyme Antibody Method”, Hiroshi Nakura, Yoshiyuki Nagamura, Hiroshi Tsutsumi, edited by Interdisciplinary Planning Co., Ltd.
- a cytospin For blood cells or microorganisms collected from human or animal biological tissues, or cultured cells such as humans or animals or insects, if they are floating cells, use a cytospin to slide glass. After the cells are pelleted by centrifugation, the clot is made, and the clot force can be prepared according to the above method.
- the method for forming a coagulum include a method of encapsulating in agarose or a method of adding fibrinogen and then thrombin to form an artificial fibrin clot.
- Staining of a section using the enzyme-labeled antibody method can be performed, for example, by the following method.
- the inhibition of endogenous substance activity may be performed after the reaction of the antibody or antibody fragment of the present invention.
- Inhibition of the activity of the endogenous substance can be carried out, for example, using the following solution under the appropriate reaction conditions for each type of solution or section used and the force that can be reacted for 5 minutes to 1 hour at room temperature. preferable.
- Endogenous substances include substances that affect the reaction that are present in the prepared sections in immunohistochemical staining. Specific examples include endogenous peroxidase, endogenous alkaline phosphatase, and endogenous piotin.
- the cleaning solution is not particularly limited as long as it can be used as a cleaning solution, but PBS, phosphate buffer, Tris-HCl buffer, or the like can be used.
- the pH is preferably 6.5 to 7.8, more preferably 7.2 to 7.6.
- the buffer concentration is preferably 0.2 to 0.005 mol / L, but more preferably 0.1 to 0.01 mol / L! /.
- normal animal serum normal animal serum, BSA, skim milk, casein solution and the like are preferably used.
- animals used for normal animal sera non-human or mouse animals that can be used by all animal species are suitable, such as eagle, hidge, rabbit, and pig.
- normal serum normal serum of the same type as the animal species derived from the anti-mouse Ig or IgG antibody used as the secondary antibody.
- concentration of serum at the time of use is suitably 1 to 5%, which can be arbitrarily selected within the range of 0.1 to 20%.
- the blocking temperature can be freely set in the range of 4 ° C to 37 ° C.
- the blocking time can be set appropriately according to the reaction temperature. At room temperature, 10 minutes to 1 hour is preferable.
- the antibody diluent may be any antibody that can be used as a diluent, but PBS containing BSA is preferably used.
- the concentration of BSA is preferably 0.1-5%.
- surfactants can be added.
- Triton X-100, Tween 20 and the like can be used as the type of surfactant to be added.
- the concentration of the surfactant is preferably 0.005 to 0.5%, more preferably 0.01 to 0.2%.
- the antibody concentration is 0.
- the reaction temperature can be freely set in the range of 4 ° C to 37 ° C as long as the reactivity of the antibody does not change.
- the reaction time can be set according to the reaction temperature.For example, when the reaction temperature is 4 ° C, the reaction time is 1 hour or more. When the reaction temperature is room temperature, the reaction time is preferably 10 minutes to 8 hours.
- color reaction solution when peroxidase is used as a labeling enzyme, 3,3'-diamino benzidine (DAB) solution, 3-amino-9-ethylcarbazole solution and 4-clo-1-1-naphtho Can be used. It is desirable to use a DAB solution with hydrogen peroxide water added during use. Imidazole may be added as a sensitizer for color reaction using DAB solution.
- DAB 3,3'-diamino benzidine
- Imidazole may be added as a sensitizer for color reaction using DAB solution.
- alkaline phosphatase When alkaline phosphatase is used as the labeling enzyme, Fast Red, Fast Red Violet or Fast Blue salts can be used as color formers, and Neufuxin solution (Merck) or BCIP / NBT solution ( (Sigma) can also be used.
- Neufuxin solution Merck
- BCIP / NBT solution (Sigma)
- glucose oxidase is used as a labeling enzyme
- a mixed solution containing glucose, phenazine methosulfate (PMS) and chromogen is used.
- the chromogen may be any chromogen that can be reduced by PMS to produce an insoluble pigment, but for example, tetrazolium such as NBT, TNBT, BSPT, INT (all from Pierce). Salt.
- the coloring reaction time is preferably 30 seconds to 20 minutes, more preferably 1 to 10 minutes.
- a solution obtained by diluting the antibody or antibody fragment of the present invention that is not enzyme-labeled with the above diluent is reacted with the sample, washed with the above washing solution, etc., and then reacted with a secondary antibody that can bind to the antibody or antibody fragment of the present invention. It is also possible to carry out a color reaction after washing again.
- the secondary antibody may be any antibody that can bind to the antibody or antibody fragment of the present invention and is labeled for detection.
- the antibody of the present invention is a mouse monoclonal antibody, an enzyme-labeled anti-mouse Ig or IgG antibody can be used!
- reaction conditions of the enzyme-labeled antibody or antibody fragment of the present invention and the reaction conditions of the enzyme-labeled secondary antibody capable of binding to the antibody or antibody fragment of the present invention are the same as in the reaction.
- antigens are often hidden by aldehyde fixation, and contact between antigen and antibody may be inhibited. In this case, the staining property can be improved by the antigen activation treatment.
- the section can be subjected to proteolytic enzyme treatment or heat treatment.
- proteolytic enzyme can be used as long as it does not cleave at the antibody recognition site on the antigen, but limited proteases are particularly preferred, for example, trypsin, pronase, pepsin, actinase, ficin, proteinase. 1, subtilisin, papain, etc.
- the heat treatment includes heating with a microwave irradiator, an electronic range, an autoclave, a pressure cooker, a water bath, a steamer, a hot plate, or the like in water or an arbitrary buffer.
- the buffer used for the heat treatment include citrate buffer, EDTA solution, sodium hydroxide sodium citrate buffer, Tris-HCl buffer, borate buffer, glycine hydrochloride buffer, carbonate buffer, An acetate buffer or the like can be used.
- the salt concentration of the buffer is 0.0005 to 0.2 mol / L, preferably 0.001 to 0.1 mol / L.
- the buffer solution has a pH of 5.0 to 10, preferably pH 5.5 to 9.5. Further, urea aqueous solution, aluminum chloride aqueous solution, periodic acid aqueous solution and the like can also be used. The concentration of these aqueous solutions is preferably 0.1 to 7%, more preferably 1 to 5%.
- treatment such as acid or alkali treatment can also be used.
- NaOH, KOH, etc. are used for alkali treatment
- hydrochloric acid, formic acid, acetic acid, etc. are used for acid treatment.
- protein modifiers such as urea and guanidine can also be used for the antigen activation treatment.
- High-sensitivity staining methods include PAP (peroxidase anti-peroxidase) method or its modified four-step PAP method, Double bridge PAP method, PAP method using Fab fragment, Hapten sandwich method, avidin 'piotin complex formation ABC (avidin biotinylated-peroxidase complex) method, LAB (labeled avidin— biotin) method, BRAB (bridge avidin— biotin) ) Method, LSAB (labelled strept avidin biotin) method using streptavidin ⁇ lj, SABC (streptavid in biotin complex) method, CSA (catalyzed signal amplification) method using biotin tyramid, and a variation of ABC method Method using avidin antibody, method using piotin protein A, method combining PAP method and ABC method, ABC method using colloidal gold-labeled anti-peroxidase antibody, method using enzyme-labeled protein A, enzyme-labeled polymer method,
- the enzyme-labeled polymer method is a method that uses a polymer in which an enzyme and a primary antibody, or an enzyme and a secondary antibody are bound to a polymer such as dextran.
- a chromogenic enzyme such as alkaline phosphatase or glucose oxidase can be used in place of peroxidase.
- examples of such methods include avidin 'biotin complex and these chromogenic enzymes, APAAP (alkaline phosphatase-anti alkaline phosphatase) method, and indirect method using peroxidase-labeled anti-FITC antibody.
- kits include, for example, Vector Stain Kit (manufactured by Vector), Strept AB Complex (manufactured by DAKO), AB Complex (manufactured by DAKO), SAB-PO kit (manufactured by -Chilei), S AB-AP kit (-Chilei), Super Sensitive Ready-to-Use Detection Kit (BioGene x), Polyvalant staining kit (ScyTek), EPOS system (DAKO), EnVision system (DAKO), Super Sensitive Non-Biotin HRP Ready-to-Use Detection Kit (BioGenex), Simple stain system (-Chilei), etc.
- the LAB method and the LSAB method can be performed, for example, under the following conditions.
- the reaction of the antibody or antibody fragment of the present invention or after blocking the activity of endogenous substances After the reaction of the antibody or antibody fragment of the present invention or after blocking the activity of endogenous substances, it is washed with a washing solution, reacted with a piotin-labeled anti-mouse Ig antibody or a piotin-labeled anti-mouse IgG antibody, and then avidin-labeled peroxidase Alternatively, react with streptavidin-labeled peroxidase.
- the reaction conditions for the piotin-labeled anti-mouse Ig antibody or the piotin-labeled anti-mouse IgG antibody and the avidin-labeled peroxidase are the same as the reaction conditions for the above-described enzyme-labeled antibody or antibody fragment of the present invention.
- a commercially available automatic immunostaining device or the like is used. It can also be used.
- Automatic immunostaining devices include HIS-20 (manufactured by Sakura Seiki), i6000 (manufactured by Kyowa Medettas), ST5050 (manufactured by Leica), HX benchmark (manufactured by Ventana 'Japan), Autostainer (manufactured by DAKO), Horizon (Made by DAKO).
- a method suitable for the labeling substance of the antibody can be used. That is, when an enzyme is selected as a labeling substance, an optical microscope, a confocal laser scanning microscope, etc. are selected. When a fluorescent substance is selected as a labeling substance, a fluorescence microscope, a confocal laser scanning microscope, a fluorescence image analysis device, etc. are selected. In the case of a radioactive substance, autoradiography, a radiation image analyzer, etc. can be used. In the case of a luminescent substance, a luminescence image analyzer, etc. can be used.
- the image data obtained by the microscope can be processed according to the purpose, and the image data can be input as a digital signal to the image analyzer using a digital image input system such as a digital camera. can do.
- the image analyzer can measure the area, shortest diameter, longest diameter, circumference, etc. of positive staining sites, and measure the transmittance, optical concentration, absorbance, etc. of positive staining sites. Quantitative analysis can be performed according to purposes such as product positive rate and distribution.
- human STS in a sample can be quantified, for example, by the following method.
- the first anti-human STS antibody is immobilized on a 96-well plate for ELISA and then blocked with BSA-PBS. Discard the BSA-PBS and wash well with PBS. Then, prepare a human STS preparation with a known concentration or a test sample with an unknown concentration, and incubate at 4 ° C for 1 hour or at room temperature for 2 hours. After washing well with Tween-PBS, a second anti-human STS antibody that has a different epitope from the first antibody that is solidified is reacted. The second antibody is previously labeled with piotin, an enzyme, a chemiluminescent substance, or a radioactive compound.
- the concentration of the test sample can be calculated from a calibration curve prepared by serially diluting human STS standards with known concentrations.
- the method If either one of the first anti-human STS antibody and the second human STS antibody used in the above is an antibody of the present invention, only STS can be specifically measured.
- Specific combinations of the first anti-human STS antibody and the second human STS antibody include, for example, the anti-human STS monoclonal antibody KM1053 produced by the hyperidoma FERM BP-10015 of the present invention and a known anti-human.
- a combination of STS monoclonal antibody KM1049 [Cancer Research, 63, 2762 (2003)] and the like can be mentioned.
- the immunological detection reagent or immunological quantification reagent for human STS is obtained by the immunological technique shown in 2. (1) to (5) above.
- the constituent elements include an anti-human STS antibody, a carrier for immobilizing the anti-human STS antibody, a solid phase on which the anti-human STS antibody is immobilized, a labeled secondary antibody used for detection or the like.
- kit or reagent of the present invention may be combined with a device suitable for measurement to form a kit.
- the anti-human STS antibody specifically binds to human STS and does not exhibit cross-reactivity with ARS other than STS, and is not particularly limited as long as it is an antibody, but for example, the hyperidoma FER M BP-10015 of the present invention.
- the anti-human STS monoclonal antibody KM1053 and the like produced by is preferably used.
- the anti-human STS antibody used in the present invention can be a fragmented antibody fragment as required.
- antibody fragments include peptides including Fab, Fab ', F (a) 2, scFv, dsFv, diabody and CDR, VH or a fusion protein thereof, VL or a fusion protein thereof.
- the above antibody or antibody fragment can be detected using a secondary antibody, or can be directly detected by labeling the antibody.
- the secondary antibody is an antibody that can bind to the antibody. Any antibody can be used as long as it is a polyclonal antibody or a monoclonal antibody or a peptide containing Fab, Fa, F (a) 2, scFv, dsFv, diabody and CDR. Can do.
- the antibody or antibody fragment used for the secondary antibody is used after being labeled for detection.
- any known edited by Koji Ishikawa et al., Enzyme Immunoassay, Medical Shoin)
- Enzymes luminescent materials, fluorescent materials or radioisotopes
- the label is an enzyme, alkaline phosphatase, peroxidase, luciferase, etc.
- the label is a luminescent substance, attalide-umester, mouth fins, etc.
- the label is a fluorescent substance, green fluorescein protein, red fluorescent protein, Sense protein, FITC, etc., and 14C, 32P, 1251, etc. can be used for radioisotopes.
- detection can be performed using labeled avidin, streptavidin, or the like using piotin labeling.
- a method of labeling an antibody or antibody fragment with the above-mentioned label a method of genetic engineering binding or a method of chemical binding is used. Methods for genetic engineering are described in the literature [Proc. Natl. Acad. Sci. USA, 93, 974 (1996); Proc. Natl. Acad. Sci. USA, 93, 7826 (1996)]. Can be done according to.
- the chemical bonding can be performed according to the method described in the literature [Science, 261, 212 (1993)].
- a method of chemically combining radioisotopes can be performed according to the method described in the literature [Antibody Immunoconjugates and Radiopharmaceuticals, 3, 60 (1990); Anticancer Research, 11, 2003 (199 1)]. .
- Examples of the method for measuring the amount of label include an absorbance method (colorimetric method), a fluorescence method, a luminescence method, and a radioactivity method.
- the label is an enzyme
- the amount of the label can be measured by reacting the enzyme substrate with the enzyme and measuring the produced substance.
- the amount of beloxidase can be measured by, for example, an absorbance method or a fluorescence method.
- an absorbance method for example, a reaction between peroxidase and its substrate hydrogen peroxide and a chromogenic chromogen is performed, and the absorbance of the reaction solution is measured with a spectrophotometer or the like.
- the method of measuring with is mentioned.
- the oxidative coloring chromogen include a leuco chromogen and an acid coupling chromogen.
- Leuco-type chromogens are substances that are converted to pigments alone in the presence of peracid-active substances such as peracid hydrogen and peroxidase.
- peracid-active substances such as peracid hydrogen and peroxidase.
- CCAP 10-N-carboxymethylcarbamoyl-3,7-bis (dimethylamino) -10H-phenothiazine
- MCDP 10-N-methylcarbamoyl-3,7-bis (dimethylamino) -10H-phenothiazine
- DA-64 4,4, -bis (dimethylamino) diphenylamine sodium salt
- BCMA bis [3-bis (4-phenylphenol) methyl-4-dimethylaminophenol] amine
- Oxidative coupling chromogen is a substance in which two compounds are acid-coupled to form a dye in the presence of peroxide active substances such as hydrogen peroxide and peroxidase.
- peroxide active substances such as hydrogen peroxide and peroxidase.
- the combination of the two compounds include a combination of a coupler and an aryline (Trinder reagent), a combination of a coupler and a phenol.
- the coupler include 4-aminoantipyrine (4-AA) and 3-methyl-2-benzothiazolinone hydrazine.
- Examples of a method for measuring the amount of peroxidase by a fluorescence method include a method in which peroxidase is reacted with a combination of peroxyhydrogen and its fluorescent substance, and the intensity of the generated fluorescence is measured. can give.
- Examples of the fluorescent substance include 4-hydroxyphenol acetic acid, 3- (4-hydroxyphenol) propionic acid, and coumarin.
- the amount of alkaline phosphatase can be measured by, for example, a luminescence method.
- the method for measuring the amount of alkaline phosphatase by the luminescence method include a method of reacting alkaline phosphatase with its substrate and measuring the luminescence intensity of the produced luminescence with a luminescence intensity meter.
- alkaline phosphatase substrates include 3- (2, -spiroadamantane) -4-methoxy-4- (3, -phosphoryloxy) phenol-1,2-dioxetane 'disodium salt.
- AMPPD 2-Chloroguchi-5- ⁇ 4-Methoxyspiro [1,2-dioxetane-3,2,-(5, -Chlorochi) tricyclo [3.3.1.13,7] decane] -4-yl ⁇ Phenol phosphate 'Disodium salt (CDP-StarTM), 3- ⁇ 4-methoxyspiro [1,2-dioxetane-3,2,-(5, -cloguchi) tricyclo [3.3.1.13, 7] decane ]-4-yl ⁇ Phenol phosphate 'Disodium salt (CSPDTM), [10-Methyl-9 (10H) -Ataridiylidene] Phenoxymethyl phosphate' Disodium salt (LumigenTM APS-5) Etc.
- the amount of ⁇ -D-galactosidase can be measured by, for example, an absorbance method (colorimetric method).
- an absorbance method colorimetric method
- the method for measuring the amount of ⁇ -D-galactosidase by the absorbance method include, for example, a method of reacting j8-D-galactosidase with its substrate and measuring the absorbance of the reaction solution with a spectrophotometer, etc. Can be raised.
- the substrate for j8-D-galactosidase include 2-chloro-4-nitrophenol 13-D-galactoside.
- the amount of radioisotope can be determined by measuring the radioactivity with a scintillation counter or the like.
- a carrier for immobilizing the anti-human STS antibody any carrier can be used as long as it can bind and hold the antibody.
- materials formed by molding various polymer materials to suit the application are used. It is done.
- the shape of the carrier for immobilizing the antibody and the like is fine particles such as tubes, beads, plates and latex, and the force such as a stick.
- the materials are polystyrene, polycarbonate, polyvinyltoluene, polypropylene, polyethylene, polyvinyl chloride, nylon, polymethacrylate.
- polymer materials such as silicate, gelatin, agarose, cellulose and polyethylene terephthalate, glass, ceramics, magnetic particles and metals.
- a known method such as a physical method and a chemical method or a combination thereof can be used.
- physical bonds include physical adsorption.
- the chemical bond include a covalent bond and a non-covalent bond.
- non-covalent bonds include electrostatic bonds, hydrogen bonds, hydrophobic bonds, and coordinate bonds.
- a polystyrene 96-well immunoassay microterplate prepared by immobilizing peptides in a hydrophobic phase.
- the antibody to be immobilized may be directly immobilized on the solid phase, or the antibody may be immobilized on the solid phase after passing through piotin-avidin or the like.
- the solid phase on which the above-mentioned anti-human STS antibody is immobilized protects the functional groups remaining on the carrier by blocking.
- a substance used for blocking in an immunoassay usually a protein, a surfactant, a commercially available blocking reagent, etc. are used, but as a normal protein used for blocking of the present invention, BSA, KLH or casein Etc. are used.
- Examples of the diluted solution of the biological sample include an aqueous solution containing a stabilizer in a surfactant or a buffer.
- the aqueous solution should be prepared as an isotonic solution with salts, sugars, buffers, etc., in order to prevent changes in serum component concentration due to expansion and contraction of blood cells such as red blood cells.
- the salt is not particularly limited, and examples thereof include alkali metal halides such as sodium chloride and potassium salt.
- the saccharide is not particularly limited, and examples thereof include sugar alcohols such as mannitol and sorbitol.
- reaction buffer may be used as long as the antibody-immobilized antibody on the solid phase and the antigen in the biological sample can undergo a binding reaction.
- surfactants preservatives, stabilizers, reaction accelerators or enzyme activity regulators may be added. Any washing solution can be used as long as unreacted substances can be removed and washed, and the antigen-antibody reaction is not affected.
- a buffer, a surfactant, a protein such as BSA or casein, an antiseptic or a stabilizer may be added. For example, Tween-PBS is used.
- the buffer used in the sample dilution, reaction buffer, or washing solution is not particularly limited as long as the buffer used in the buffer has a buffering capacity.
- Good buffers include, for example, MES (2-morpholinoethanesulfonic acid) buffer, bis-tris [bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane] buffer, ADA [N- (2-acetamido ) Iminoniacetic acid] buffer, PIPES [piperazine-N, N, -bis (2-ethanesulfonic acid)] buffer, ACES ⁇ 2- [N- (2-acetamido) amino] ethanesulfonic acid ⁇ buffer, MOPSO (3-morpholino-2-hydroxypropanesulfonic acid) buffer, BES ⁇ 2- [ ⁇ , ⁇ -bis (2-hydroxyethyl) amino] ethanesulfonic acid ⁇ buffer, MOPS (3-morpholinopropanesulfonic acid) Buffer, TES ⁇ 2- ⁇ N- [Tris (hydroxymethyl) methyl] amino ⁇ ethanesulfonic acid> buffer, HEPES [N- (2-hydroxyeth
- Examples of the enzyme activity regulator and enzyme stabilizer include metal ions such as magnesium ion, manganese ion, and zinc ion.
- the content of these metal ions in the reagent is not particularly limited as long as the enzyme is stabilized in the measurement.
- Examples of antiseptics include sodium azide and antibiotics.
- the content of these preservatives in the reagent is not particularly limited as long as it is such a content that the substance to be measured in the sample can be appropriately measured in the measurement.
- Human STS reference materials include human STS obtained by genetic recombination technology or obtained from biological samples, cells expressing human STS, and partial peptides of human STS.
- An immunological detection reagent or kit for human STS in a specimen of the present invention and an immunological quantitative reagent or kit are used for determination or diagnosis of human STS-related diseases, selection of drugs suitable for treatment of human STS-related diseases, It can be used for the determination or diagnosis of human STS-related diseases.
- the human STS-related disease includes any disease, regardless of whether it is mild or severe, as long as human STS is involved in the pathological condition.
- Examples of human STS-related diseases include estrogen-dependent diseases in which human STS is involved in pathological conditions, and specific examples include estrogen-dependent tumors in which human STS is involved in pathological conditions.
- Examples of estrogen-dependent tumors include tumors with estrogen-dependent cell proliferation, such as malignant tumors, benign tumors, and skin diseases.
- malignant tumors include breast cancer, uterine cancer, ovarian cancer, prostate cancer, and Skills gastric cancer.
- Breast cancer and uterine cancer are preferred.
- breast cancer include ductal cancer, lobular cancer, Paget's disease and the like, and invasive ductal cancer, in which breast cancer is preferred, is particularly preferable.
- endometrial cancer also called endometrial cancer, is particularly preferred.
- the disease site may be a primary lesion or a metastatic lesion.
- Examples of benign tumors include endometriosis, uterine adenomyosis, uterine fibroids, etc., but eclampsia and eclampsia are preferred.
- Examples of skin diseases include ichthyosis.
- human STS in the specimen is detected, or human STS is healthy.
- human STS is healthy.
- the abundance of human STS is increased as compared with normal tissues, it is determined that human STS is positive or that human STS is up-regulated.
- Such a patient is determined or diagnosed as having a human STS-related disease.
- a drug suitable for the treatment of the human STS-related disease can be selected.
- human STS-related diseases include estrogen-dependent diseases in which human STS is involved in the pathology, a drug suitable for the treatment of estrogen-dependent diseases may be selected.
- Specific examples of drugs suitable for the treatment of human STS-related diseases include STS inhibitors.
- Examples of drugs suitable for the treatment of estrogen-dependent diseases include hormone therapy agents.
- any STS inhibitor may be used as long as it has a function of inhibiting the function of STS.
- nortropiny ⁇ arylsulfonylurea or a derivative thereof [Bioorg anic & Medicinal Cnemistry Letters, 1 ⁇ , 3b / '3 (2003)], estrone— 3—O—sulfamate3 ⁇ 4 ⁇ or its derivatives, 2-difluoromethyloestrone 3—O—sulphamate [Biochemical & Biophysic al Research Communications, 317, 169 (2004)], bipheny ⁇ 4—O— sulfamate or ⁇ masano derivatives, 2 ', 4'-dicyanobiphenyl-4-0-sulfamate [Journal of Steroid Biochemistry & Molecular Biology, 87, 141 (2003)], estrone derivatives [Bioorganic & Medicinal Chemis try, 11, 1685 (2003)], 2-Alkylchromen- 4- one 6-0-sulfamates [J
- the hormone therapy agent includes any drug that has a function of inhibiting the function of estrogen, but an anti-estrogen agent, a selective aromatase inhibitor, a luteinizing hormone-stimulating hormone inhibitor or Specific examples include progesterone preparations. Examples include goseralin and medroxyprogesterone acetate.
- the immunological detection reagent or kit for human STS in the specimen of the present invention and the immunological determination reagent or kit can be used for the determination or diagnosis of the pathological condition of human STS-related diseases. .
- Examples of the determination or diagnosis of the pathology of human STS-related diseases include grasping the current state of human STS-related diseases and predicting prognosis.
- the current status of human STS-related diseases includes, for example, the degree of progression, progression, exacerbation, or tolerance after treatment.
- the prognosis of the disease includes the possibility of recurrence, the degree of metastasis, or the survival rate of affected patients.
- Purified human STS was also obtained for human placenta tissue as follows. All operations were performed at 4 ° C.
- the obtained microsomal fraction was prepared by adding buffer B [lmmol / L EDTA, lmmol / L dithioerythreitol (DTE), 0.05% phenylmethylsulfurfluoride (PMSF), 0.5% triton X-100. 10 mmol / L Tris-hydrochloric acid buffer solution (PH7.5)] was added and stirred at room temperature for 1 hour to dissolve.
- the eluted fraction was passed through a phenyl sepharose column equilibrated with buffer B, washed with a sufficient amount of the same buffer, and eluted with the same buffer containing 1.25% Triton X-100.
- the elution fraction thus obtained was used as purified human STS.
- Purified human STS was tested for purity using SDS-denatured polyacrylamide gel electrophoresis (hereinafter referred to as SDS-PAGE).
- Figure 1 shows the results of SDS-PAGE staining of purified human STS obtained with Kumashi brilliant blue. As indicated by the arrow, purified human STS was stained as a single band with a molecular weight of 63 KDa, and the purity of purified human STS was estimated to be 90% or more.
- Purified human STS obtained in (1) above was administered to 5-week-old female mice (Balb / c) together with 2 mg of aluminum gel and pertussis vaccine (manufactured by Chiba Serum Research Laboratories) 1 X 10 9 cells, and 2 weeks later More similarly prepared immunogen was administered once a week for a total of 4 times. Blood was collected from the fundus venous plexus, the serum antibody titer was examined by the enzyme immunoassay shown below, and the spleen was removed 3 days after the final immunization from the mouse that showed a sufficient antibody titer.
- the spleen is shredded in MEM medium (manufactured by Nissui Pharmaceutical), loosened with tweezers, centrifuged (1200 rpm, 5 minutes), the supernatant was discarded, and Tris monosalt-ammoum The cells were treated with a buffer solution (pH 7.65) for 1-2 minutes to remove erythrocytes, washed 3 times with MEM medium, and used for cell fusion.
- MEM medium manufactured by Nissui Pharmaceutical
- tweezers centrifuged (1200 rpm, 5 minutes
- Tris monosalt-ammoum The cells were treated with a buffer solution (pH 7.65) for 1-2 minutes to remove erythrocytes, washed 3 times with MEM medium, and used for cell fusion.
- the purified human STS obtained in (1) above was used as the antigen for Atsey.
- BSA was used as the negative control antigen.
- Purified human STS or BSA was dispensed into a 96-well EIA plate at 50 ⁇ L / well and left at 4 ° C for adsorption. After washing, BSA-PBS was added at 100 / z L / well and reacted at room temperature for 1 hour to block remaining active groups. BSA—PBS was discarded, and the immunized mouse antiserum, anti-human STS monoclonal antibody culture supernatant or purified monoclonal antibody was dispensed at 50 ⁇ L / well and allowed to react for 2 hours.
- peroxidase-labeled Usagi anti-mouse immunoglobulin (Dako) (50 ml / well) was added at 50 L / well and allowed to react for 1 hour at room temperature.
- ABTS substrate solution [2, 2 Dissolve 0.55 g of '-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) ammonium in 1 L of 0.1 mol / L citrate buffer (pH 4.2) and peroxidize immediately before use.
- a solution containing hydrogen water added at 1 ⁇ L / mL is colored with 50 L / well and colored, and the absorbance at 415 nm (hereinafter referred to as OD415) is applied to a plate reader (NJ2001; Nippon Intermed). ).
- the 8-azaguan metabolite mouse myeloma cell line P3-U1 [European Journal of Immunology, 6, 511 (1976)] was cultured in normal medium, and at least 2 X 10 7 cells were secured during cell fusion. It used for cell fusion.
- mice spleen cells obtained in (2) above and the myeloma cells obtained in (4) were mixed at a ratio of 10: 1, centrifuged (1200 rpm, 5 minutes), the supernatant was removed, after thoroughly loosened the precipitated cell group, while stirring, 37 ° C, polyethylene of glycol -1000 (PEG-1000) 2g, MEM medium 2mL and dimethylsulfoxide 0.7mL of a mixture of 1 X 10 8 cells mouse splenocytes Add 0.2 to 1 mL per minute, add 1 to 2 mL of MEM medium several times every 1 to 2 minutes, and then add MEM medium so that the total volume is 50 mL. After centrifugation (900 rpm, 5 minutes), the supernatant was removed, the cells were loosened gently, and the cells were suspended in lOOmL of HAT medium gently by suction and suction with a pipette.
- the monoclonal antibodies produced by the Hypridoma cell line KM1053 and Hypridoma cell line KM1049 are called anti-human STS monoclonal antibody KM1053 and anti-human STS monoclonal antibody KM1049, respectively.
- mice (Balb / c) treated with pristane were injected intraperitoneally with 5 to 20 ⁇ 10 6 cells Z each of the mice obtained in (5) above. After 10-21 days, the hyperidoma developed ascites tumor. Ascites was collected from mice with ascites (1-8 mL / animal) and centrifuged (3000 rpm, 5 minutes) to remove solids. The obtained ascites was prepared by the fpr from the force prillic acid precipitation method [Antioodies-A Laooratory Manual, Cold Spring Harbor Laboratory, (1988)] and used as a purified monoclonal antibody.
- the antibody subclass was determined by enzyme immunoassay using a sub-clustering kit (manufactured by ZYMED). The results are shown in Table 1.
- Plasmid pSVL—STS [J. Biol. Chem., 264, 13865 (1989)] (lng / L) containing human STS gene 0.5 L, 10-fold concentration of Pfo polymerase buffer 5 L, 2 mmol / L dNTP 2 L 40 ⁇ mol / L of the primer having the nucleotide sequence shown in SEQ ID NOs: 1 and 2, respectively, 0.5 ⁇ L, DMSO 5 L, Pfo polymerase (STRATAGENE) 0.5 ⁇ L, and sterile water 36 ⁇ L Overlay with mineral oil and heat at 94 ° C for 5 minutes, then perform 16 reaction cycles consisting of 94 ° C for 1 minute, 50 ° C for 1 minute and 72 ° C for 2 minutes, followed by 72 ° C.
- the reaction was carried out at C for 7 minutes.
- the PCR product was fractionated by agarose gel electrophoresis, and the obtained amplified fragment of about 1.7 kb was extracted using the GENECLEAN Spin Kit (manufactured by BIO101).
- the extracted fragment was digested with ⁇ lHI and 1 and ligated to pQE30 (QIAGEN) extinguished with ⁇ iHI and ⁇ ml using DNA Ligation Kit ver.2 (Takara Shuzo).
- Escherichia coli DH5 ⁇ strain was transformed by the method of [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)].
- a plasmid was extracted from the obtained transformant using a plasmid extraction kit (manufactured by QIAGEN) to obtain an expression plasmid pQE-STS.
- the DNA sequence of pQE-STS was confirmed using DNA Sequencer 373 (Perkin Elmer dry soil) and BigDye Terminator ycle Sequencing Fb Ready Reaction Kit (Perkin Elmer). In addition to the areas where the changes were made, there was no change.
- pQE-STS was introduced into Escherichia coli M15 [pREP4] strain in the same manner as described above to prepare human STS-expressing Escherichia coli strain M15 [pREP4] / pQE-STS.
- the STS-expressing E. coli strain M15 [pREP4] / pQE-STS strain prepared in (1) above is 50 mg / L After culturing at 37 ° C in LB medium containing picillin and 10 mg / L kanamycin, diluting the culture medium 50 times and culturing for 1 hour, add IPTG to a final concentration of 4 mmol / L. I was accompanied. After 4 hours of culture, the cells were collected by centrifugation.
- the recovered human STS-expressing E. coli strain and purified human STS derived from human placenta are dissolved in 1-fold PAGE buffer [2% SDS, 62 mmol / L Tris-HCl buffer (pH 6.8), 10% Glycerol].
- the mixture was heat-treated at 95 ° C for 5 minutes, fractionated by SDS-polyacrylamide electrophoresis [Ant3 ⁇ 4odies-A Laboratory Manual, Cold Spring Harbor Laboratory, (1988)], and then blotted on a PVDF membrane. After blocking the membrane with BSA-PBS, anti-human STS monoclonal antibody KM1 053 or anti-human STS monoclonal antibody KM1049 was reacted at room temperature for 2 hours.
- a peroxidase-labeled anti-mouse immunoglobulin antibody (manufactured by DAKO) was reacted as a second antibody at room temperature for 1 hour. After washing thoroughly with Tween-PBS, detection was performed using an ECL-detection kit (Amersham) and exposed on an X-ray film.
- FIG. 3 shows the results.
- Anti-human STS monoclonal antibody KM1053 and anti-human STS monoclonal antibody KM1049 both reacted not only with placenta-derived purified human STS obtained in Example 1 (1) but also with recombinant human STS expressed in E. coli.
- anti-human STS monoclonal antibody KM1053 and anti-human STS monoclonal antibody KM1049 can detect human STS by Western blotting and can be applied to the determination or diagnosis of various diseases involving STS. It was done.
- the plasmid pSVL-STS containing the human STS gene [J. Biol. Chem., 264, 13865 (1989)] was digested with restriction enzymes 1 and ⁇ , and the resulting digested fragments were separated by agarose gel electrophoresis, and about A fragment containing a 2.4 kb human STS gene was extracted.
- the extracted fragment was ligated to pBlueScriptllSK (-) digested with 1 and HI, and transformed into E. coli DH5 ⁇ strain by the method of Cohen et al. [Proc. Natl. Aca d. Sci. USA, 69, 2110 (1972)]. did.
- Plasmids were extracted from the resulting transformants using a plasmid extraction kit (QIAGEN) to obtain pBS-STS.
- pBS-STS was digested with II and 20 ⁇ 1 and a fragment containing the human STS gene was obtained as described above.
- the fragment of the animal cell expression vector pcDNA3 manufactured by Invitrogen
- the expression plasmid pcSTS was obtained by inserting into the Notl-Xhol site.
- pcSTS is produced by CHO / dDXBl cells [Proc. Natl. Acad. Sci. USA, 77, 4216 (1980) as follows by the electoral position method [Cytotechnology, 3, 133 (1990)]. ] Was introduced.
- CHO / dDXBll cells were supplemented with 5% urine fetal serum (Life technologies), 0.09% baking soda (Life technologies), 1% Penicillin-streptomycin (Life technologies) 7 Cells subcultured in a medium (Life Technologies) (hereinafter referred to as A3 medium) were used.
- CHO / dDXBll cells were washed with K-PBS buffer [137 nmol / L potassium chloride, 2.7 nmol / L sodium chloride, 8.1 mmol / L disodium monohydrogen phosphate, 1.5 nmol / L dihydrogen phosphate Suspend in sodium, 4 mMol / L salt-magnesium buffer] to 8 X 10 6 cells / mL, mix 200 L of cell suspension (containing 1.6 X 10 6 cells) with 4 g of the above plasmid. did.
- K-PBS buffer [137 nmol / L potassium chloride, 2.7 nmol / L sodium chloride, 8.1 mmol / L disodium monohydrogen phosphate, 1.5 nmol / L dihydrogen phosphate Suspend in sodium, 4 mMol / L salt-magnesium buffer] to 8 X 10 6 cells / mL, mix 200 L of cell suspension (containing 1.6 X 10 6 cells) with 4
- the mixed solution was transferred to a cuvette (distance between electrodes: 2 mm), and gene introduction was performed using a GenePulser II (BioRad) device under conditions of a pulse voltage of 0.35 kV and an electric capacity of 250 F. After leaving the cuvette on ice, suspend the cell suspension in the cuvette in a cell culture vessel containing A3 medium, 37 ° C, 5% CO
- the resulting transformed cells are diluted with B3 medium to 1.25 cells / mL, and the diluted solution is dispensed in 200 L portions into a 96-well plate, subjected to single cell cloning, and transformed cells cs3- 1 Cell lines were obtained.
- Cells into which human STS was introduced were selected by measuring the arylsulfatase activity of the transformed cells obtained above.
- TT buffer 50mmol / L Tris-HCl buffer (pH7.2) containing 1% Triton X-100
- NPS p-Nitrophenylsulfate
- the beads were washed 3 times with the above lysis buffer. After washing, add 35 L of double PAGE buffer [4% SDS ⁇ 124 mmol / L Tris-HCl buffer (pH 6.8), 20% Glycerol] to the beads and heat at 95 ° C for 5 minutes.
- the treated and adsorbed protein on the precipitated beads was subjected to electrophoresis on a 10% SDS-PAGE gel.
- the fractionated protein was transferred to a PVDF membrane, and Western blotting was performed in the same manner as described in (2) above. Western blotting method KM1049 was used as the secondary antibody, and HRP-labeled Usagi anti-mouse antibody (DAKO) was used as the secondary antibody. The results are shown in FIG.
- Anti-human STS monoclonal antibody KM1053 was able to immunoprecipitate human STS, but anti-human STS monoclonal antibody KM1049 was not able to immunoprecipitate human STS. It has been shown that KM1053 can detect human STS by immunoprecipitation and can be applied to the diagnosis of various diseases related to STS.
- Human STS was detected by the immunocytostaining method using the anti-human STS monoclonal antibody obtained in Example 1 (5) as follows.
- the cells were the human STS gene-introduced cell line cs3-l cell constructed in (3) above and CDNA3 in which pcDNA3 plasmid not containing human STS gene was introduced into the parental CHO / dDXBll cell as a negative control. -1 cell was used.
- the cells were detached with EDTA, washed with PBS, and then treated with ice-cooled 100% methanol at 4 ° C for 10 minutes in order to increase the antibody permeability of the cell membrane. After washing with PBS, blocking was performed with lmg / mL human immunoglobulin (manufactured by Kappel) for 30 minutes at room temperature. The reaction was dispensed at 1 ⁇ 10 5 cells / reaction, and the culture supernatant of the anti-human STS monoclonal antibody KM1053 producing hybridoma was added and reacted at room temperature for 30 minutes.
- FITC-labeled anti-mouse immunoglobulin antibody antibody that specifically reacts with mouse immunoglobulin; Wako Pure Chemical Industries
- FITC-labeled anti-mouse immunoglobulin antibody is dispensed in 100 L / tube and protected from light at 4 ° C for 30 minutes. Reacted.
- analysis was performed with a cell analyzer (Coulter, Inc .; EPICS XL systemll).
- the anti-human STS monoclonal KM1053 does not react with CDNA3-1 cells that do not express human STS, and the cell line into which the human STS gene has been introduced cs3-l It showed specific reactivity to cells.
- the negative mouse IgGl class monoclonal antibody did not react with any cells. Therefore, anti-human STS monoclonal antibody KM1053 is It was shown that STS can be detected and applied to diagnosis of various diseases related to STS.
- the sections were kept at room temperature using the blocking solution derived from normal rabbit sera attached to the Histofine SAB-PO (M) (hereinafter referred to as “Histofine”) used in the detection step described later. And blocked for 30 minutes. After blocking, the sample was diluted with primary antibody diluent [PBS containing 0.5% BSA, 0.05% azide (disodium phosphate 32.27 g, monosodium phosphate 4.5 g, salt 80 g, distilled water 1 liter)] 8.33 The reaction was allowed to proceed overnight at 4 ° C with anti-human STS monoclonal antibody K M1053 diluted to g / mL. At this time, normal mouse IgG was simultaneously used as a negative control for the primary antibody.
- primary antibody diluent PBS containing 0.5% BSA, 0.05% azide (disodium phosphate 32.27 g, monosodium phosphate 4.5 g, salt 80 g, distilled water 1 liter)
- peroxidase blocking solution all mL of 30% hydrogen peroxide solution is adjusted with methanol to lOOmL
- Peroxidase blocking solution all mL of 30% hydrogen peroxide solution is adjusted with methanol to lOOmL
- the reaction was washed and reacted for 30 minutes at room temperature using the secondary antibody solution (Piotin-labeled anti-mouse IgG + IgA + IgM Usagi antibody) attached to the Histofine.
- the reaction was washed and reacted at room temperature for 30 minutes using the avidin-labeled peroxidase solution attached to the Histofine.
- DAB color development was performed as follows.
- anti-human STS monoclonal KM1053 capable of staining 90% or more of cancer tissue is an antibody suitable for immunohistochemical staining of cancer
- anti-human STS monoclonal K M1053 Since human STS can be detected by immunocytostaining, it has been shown that it can be applied to the diagnosis of various diseases involving STS.
- PCR cloning of the ARS A gene was performed from the human placenta cDNA library (Clontech).
- cDNA library (0.5 ⁇ g / ⁇ L) 20 ⁇ L, 10-fold concentration of KOD polymerase buffer 5 ⁇ L, 2 mmol / L dNTP 2 ⁇ 40 ⁇ mol / L Primer 0.5 ⁇ L, DMSO 5 ⁇ KOD polymerase (Toyobo Co., Ltd.) 0.5 ⁇ L, and sterilized water 21.5 L, mineral oil is overlaid, heated at 94 ° C for 5 minutes, then at 94 ° C 1 25 reaction cycles of 1 minute at 45 ° C and 2 minutes at 72 ° C were performed for 25 minutes, followed by a reaction at 72 ° C for 10 minutes.
- the PCR product was fractionated by agarose gel electrophoresis, and the obtained amplified fragment of about 1.5 kb was extracted using GENECLEAN Spin Kit (manufactured by BIO101). The extracted fragment was used as a saddle and the same PCR reaction was performed as above, and the amplified fragment was extracted as described above.
- the obtained amplified fragment was digested with Hindm and ai, and ligated to pBluescript SK (-) digested with Hindlll and al using a DNA ligation kit ver.2 (Takara Shuzo), followed by the method of Cohen et al. [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)] was transformed into E.
- Plasmids were extracted from the resulting transformants using a plasmid extraction kit (KPromega) to obtain pBS-ARS A2 and pBS-ARS 5.
- pB The DNA sequences of S-ARS A2 and pBS-ARS 5 were confirmed using DNA Sequencer 377 (Perkin Elmer) and BigDye Terminator Cycle sequencing FS Ready Reaction Kit (Perkin Elmer: ⁇ ). It was found that there was a single mutation in ARS A2 and a deletion mutation at positions 464-526 in pBS-ARS A5.
- pBS-ARS A2 was digested with ilindlll and ⁇ ⁇ ⁇ , separated by agarose gel electrophoresis, and the extracted fragment (0.8 kbp) was extracted from pBS-ARS A5 ilindm- PBS-ARS A ′ containing the translation region of complete ARS A was obtained by inserting into the S1BI fragment (3.5 kbp).
- the target plasmid pBS-ARS is obtained by digesting pBS-ARS A 'with ⁇ MI and generating fragments of 0.5, 0.6, and 3.4 kbp by analysis of agarose electrophoresis and by sequencing near the mutation point. It was confirmed that A 'was acquired.
- pBS-ARS A ′ was digested with Hindlll and ⁇ , and a fragment containing ARS ⁇ was obtained in the same manner as described above. The fragment was inserted into the Hiadin-ai site of animal cell expression vector pAGE210 [J. Biochem., 101, 1307 (1987)] to obtain an expression plasmid PAGE210-ARS A.
- PAGE210-ARS A was digested with ⁇ and linearized. After phenol chloroform extraction, ethanol precipitation was performed, and the recovered linear plasmid was dissolved in 1 ⁇ g / L.
- CHO / DG44 cells Somatic Cell and Moleculer Genetics, 12, 555 (1986)] have 10% urine fetal serum (Life technologies), 1% HT Supplement (Life technologies), 1% Penicillin- A subculture of IMDM medium (Life technologies) (hereinafter referred to as A1 medium) supplemented with streptomycin (Life technologies) was used.
- CHO / DG44 cells in K-PBS buffer [137 nmol / L potassium chloride, 2.7 nmol / L sodium chloride, 8.1 mmol / L disodium monohydrogen phosphate, 1.5 nmol / L monosodium dihydrogen phosphate, 4 mmol / L Suspended in a magnesium chloride buffer to give 8 ⁇ 10 6 cells / mL, and 200 ⁇ L of the cell suspension (containing 1.6 ⁇ 10 6 cells) was mixed with 4 g of the above linear plasmid.
- the mixture was transferred to a cuvette with a distance between electrodes of 2 mm, and gene introduction was performed using a GenePulser II (BioRad) device under conditions of a pulse voltage of 0.30 kV and an electric capacity of 250 F.
- the cell suspension in the cuvette was suspended in 10 mL of A1 medium, and 100 L was dispensed into a 96-well plate at 37 ° C in a 5% carbon dioxide incubator. .
- B1 medium IMDM medium supplemented with hygromycin B (hereinafter referred to as B1 medium), and the culture was continued. Passaging was continued while diluting, and a transformed cell line resistant to hygromycin B was obtained about 2 weeks after gene transfer.
- the obtained transformed cells were subcultured three times in B1 medium supplemented with 50, 100 or 500 nmol / L Methotrexate (MTX) (approximately 2 weeks). ) To obtain strains resistant to each concentration of MTX. In addition, the obtained expression strain was subcultured in EX-CELL 301 (manufactured by JRH Bioscience) to acclimate the serum, and transformed cells into which ARS A had been introduced were obtained.
- EX-CELL 301 manufactured by JRH Bioscience
- the aryl sulfatase activity of the transformed cells obtained above was measured by the following method, and cells into which ARS A had been introduced were selected.
- NCS p-Nitrocatecholsulfate
- the reaction was carried out. Extract 100 L of the reaction solution at 0 and 30 minutes after the start of the reaction, mix with 50 ⁇ L of IN NaOH to stop the reaction, and then measure the absorbance at 490 nm using a Microplate reader benchmark (manufactured by BIO-RAD). The enzyme activity of the cells was determined. The results are shown in Figure 7-A. Control cell line introduced with plasmid pAGE210 not containing ARS A gene Vector 1 cell line and transformation of pAGE210-ARS A plasmid containing ARS A gene into the ⁇ ⁇ (100) cell line were compared for arylsulfatase activity However, it was confirmed that the transformant 7 (100) cell line has ararylsulfatase activity.
- a plasmid pMPSVHE-ASB [Gene, 68, 213 (1988)] containing the human-derived ARS B gene was digested with restriction enzyme E £ 2RI and blunt-ended with Blunting Kit (Takara Shuzo) and digested with ⁇ HI.
- the obtained digested fragments were separated by agarose gel electrophoresis, and then a fragment containing about 2.3 kb of ARS B was extracted using GENECLEAN Spin Kit (manufactured by BIO101).
- the extracted fragment was inserted into the ⁇ lHI-site of animal cell expression vector pAGE210 [J. Biochem., 101, 1307 (1987)] using DNA Ligation Kit ver.2 (Takara Shuzo).
- Escherichia coli J Ml 10 strain (dam ", dcm") was transformed with the vector by the method of Cohen et al. [ Proc . Natl. Acad. Sci. USA, 69, 2110 (1972)]. Plasmid extraction kit (P The plasmid was extracted using romega) to obtain pAGE210-ARS B.
- the obtained transformed cells are subcultured 3 times (approximately 2 weeks) in B1 medium supplemented with 50, 100 or 500 nmol / L Methotrexate (MTX).
- MTX Methotrexate
- a strain resistant to each concentration of MTX was obtained.
- the obtained expression strain was subcultured in a medium of EX-CELL 301 (manufactured by JRH Bioscience) to acclimate with serum.
- the cells into which ARS B had been introduced were selected by measuring the aryl sulfatase activity of the transformed cells obtained above.
- pAGE210-ARS D is transferred to CHO / DG44 cells [Somatic Cell and Molecular Genetics, 12, 555 (1986)] as follows by the electoral position method [Cytotechnology, 3, 133 (1990)]. Introduced.
- PAGE210-ARS D was digested with sputum and linearized. The reaction solution was extracted with phenol chloroform and then recovered by ethanol precipitation, and the recovered linear plasmid was dissolved. On the other hand, CHO / DG44 cells were supplemented with 10% urine fetal serum (Life technologies), 1% HT Supplement (Life technologies), 1% Penicillin-streptomycin (Life technologies) A subculture of IMDM medium (Life technologies) (hereinafter referred to as A4 medium) was used.
- CHO / DG44 cells in K-PBS buffer [137 nmol / L potassium chloride, 2.7 nmol / L sodium chloride, 8.1 mmol / L disodium monohydrogen phosphate, 1.5 nmol / L sodium dihydrogen phosphate, 4 mmol / L Suspended in a magnesium chloride buffer solution to give 8 ⁇ 10 6 cells / mL, and 200 L of cell suspension (containing 6 ⁇ 10 6 cells) was mixed with 4 g of the linear plasmid.
- the mixture was transferred to a cuvette (distance between electrodes: 2 mm), and gene introduction was performed using a GenePulserll (BioRad) apparatus under conditions of a pulse voltage of 0.30 kV and an electric capacity of 250 F. After leaving the cuvette on ice, the cell suspension in the cuvette was suspended in four 10 cm dishes containing 12 mL of A medium and cultured in a 37 ° C, 5% CO incubator. After culturing for 1 day, 10%
- IMDM medium (Life technologies) supplemented with baby serum (Life technologies), 1% Penicillin—streptomycin (Life technologies), 300 ⁇ g / mL hygromycin (hereinafter referred to as B4 medium)
- B4 medium 300 ⁇ g / mL hygromycin
- the obtained transformed cells were serially transferred 3 times approximately every 2 weeks in B1 medium supplemented with 50, 100 or 500 nmol / L Methotrexate (MTX). And strains resistant to each concentration of MTX were obtained. In addition, the obtained expression strain was subcultured in B4 medium to make it acclimatized with serum.
- MTX Methotrexate
- the cells into which ARS D was introduced were selected by measuring the arylsulfatase activity of the transformed cells obtained above.
- Cells suspended in 100 mmol / L Tris-HCl buffer (pH 7.5) were sonicated and centrifuged at approximately 8000 X g for 5 minutes. It measured using Protein assay reagent kit (made by PIERCE).
- the reaction was conducted at 37 ° C for 4 hours.
- the absorbance at 415 nm of the reaction solution was measured using a Microplate reader Benchmark (manufactured by BIO-RAD) to determine the aryl sulfatase activity of the cells.
- Plasmids were extracted from the resulting transformants using a plasmid extraction kit (Promega) to obtain pBS-ARSE.
- pBS-ARS E was digested with Kmil and tUndlll to obtain a fragment containing ARS E as described above. The fragment was inserted into the KMl-Mindlll site of animal cell expression vector pAGE210 [J. Biochem., 101, 1307 (1 987)] to obtain expression plasmid pAGE210-ARSE.
- the obtained transformed cells were diluted with B4 medium to 1.25 cells / mL, dispensed 200 L each into a 96-well plate, and single cell cloning was performed. Furthermore, in order to carry out transgene amplification, the transformed cells obtained were passaged three times in sequence in B4 medium supplemented with 50, 100 or 500 nmol / L Methotrexate (MTX) (approximately 2 weeks). ⁇ Resistant to various concentrations of MTX Acquired stocks. In addition, the obtained expression strain was subcultured in B4 medium to make it acclimatized.
- MTX Methotrexate
- the cells into which ARS E had been introduced were selected by measuring the aryl sulfatase activity of the transformed cells obtained above.
- Cells suspended in TC buffer [50 mmol / L Tris-HCl buffer (pH 7.8) containing 1% CHAPS] were centrifuged at approximately 8000 X g for 5 minutes and 50 ⁇ L of supernatant and p-Nitrophenylsulfate ( NPS) substrate solution [50 mmol / L Tris-HCl buffer solution ( ⁇ 7.8) containing 20 mmol / L NPS, 1% CHAPS] 50 / ⁇ L was mixed and reacted at 37 ° C for 5 minutes.
- TC buffer 50 mmol / L Tris-HCl buffer (pH 7.8) containing 1% CHAPS
- the absorbance at 415 nm of the reaction solution was measured using a Microplate reader Benchmark (manufactured by BIO-RAD) to determine the enzyme activity of the cells.
- the protein concentration of the supernatant was measured using a BCA Protein assay reagent kit (PIERCE).
- Plasmids were extracted from the obtained transformants using a plasmid extraction kit (Promega) to obtain pBS-ARS F.
- pBS-ARS F was digested with 1 and ffindlll to obtain a fragment containing the gene encoding ARS F in the same manner as described above. The fragment was inserted into the I-Hindlll site of an animal cell expression vector pAGE210 [J. Biochem., 101, 1307 (1987)] to obtain an expression plasmid pAGE210-ARS F.
- the obtained transformed cells were diluted with B4 medium to 1.25 cells / mL, dispensed 200 L each into a 96-well plate, and single cell cloning was performed. Furthermore, in order to carry out transgene amplification, the transformed cells obtained were passaged three times in sequence in B4 medium supplemented with 50, 100 or 500 nmol / L Methotrexate (MTX) (approximately 2 weeks). As a result, transformed cell lines resistant to various concentrations of MTX were obtained.
- MTX Methotrexate
- the cells into which ARS F had been introduced were selected by measuring the arylsulfatase activity of the transformed cell line obtained above.
- the protein amount of was measured using a BCA Protein assay reagent kit (PIERCE).
- the resulting cell-free extract of human STS gene-introduced cells (cells suspended in 100 mmol / L Tris-HCl buffer ( ⁇ 7.5) were sonicated and centrifuged at approximately 8000 X g for 5 minutes.
- Protein 5 ⁇ g / ray Cell-free extract of cells transfected with ARS D, ARS E, and ARS F genes [LOOmmol / L Tris-hydrochloric acid buffer (PH7.5) suspended ultrasonically, approximately 8000 X g After centrifugation for 5 minutes, the supernatant protein, 20 g / lane], was fractionated by SDS-polyacryl electrophoresis and transferred to a PVDF membrane. After blocking with BSA-PBS, anti-human STS monoclonal antibody KM1049 was reacted at room temperature for 2 hours.
- a peroxidase-labeled anti-mouse immunoglobulin antibody (manufactured by Dako) was reacted as a second antibody for 1 hour at room temperature. After washing with Tween-PBS, detection was performed using an ECL-detection kit (Amersham) and exposed on an X-ray film.
- Protein A bepharose beads (Protein A bepharoseTM and L-4B, Amersham Biosciences, Buckinghamshire, UK) is swollen in distilled water in a microtube and visually confirmed that the amount of beads is about 20 L. While I was barking. After vortexing, leave on ice for 10 minutes to allow the beads to settle naturally, discard the supernatant, wash the beads again with lmL of distilled water, and centrifuge for 12 seconds with a desktop simple centrifuge to sediment the beads. (Hereafter, the desktop simple centrifuge was used for the sedimentation of beads). The supernatant was discarded, Wash, buffer - After standing [0.1 mol / L Tris containing 0.05% Tween 20 HCl buffer (.
- the cross-reactivity of anti-human STS monoclonal antibody KM1049 and anti-human STS monoclonal antibody KM1053 to ARS A and ARS B was examined by binding ELISA in which human STS as ARS A, ARS B and ARS C was solidified.
- Animal cell expression purification ARS A, ARS B and purified human STS obtained by the method described in Example 1 (1) were immobilized on a plate at 2 ⁇ g / mL, and the method described in Example 1 (3) Similarly, a binding ELISA was performed, and the results are shown in FIG.
- the anti-human STS monoclonal antibody KM1053 is a monoclonal antibody specific for human STS that does not react with arylsulfatase other than human STS. It was shown that there is.
- Anti-human STS monoclonal antibody KM1049 purified antibody was subjected to piotin treatment using NHS-Lc-Biotin (PIERCE). That is, add 250 mL of 0.5 mg / L carbonate buffer (pH 9.2) to purified anti-human STS monoclonal antibody KM1049 at a concentration of 1 mL / mg / mL, and add 250 ⁇ L of lmg / mL. NHS-Lc-Biotin (lmg / mL) was added, and the mixture was stirred at room temperature for 3 hours. The product dialyzed overnight in PBS was used as the piotinylated anti-human STS monoclonal antibody KM1049.
- PIERCE 0.5 mg / L carbonate buffer
- Human STS gene-introduced cell line Human STS was purified from cs3-l cells using anti-human STS monoclonal antibody KM1053 antibody strength ram as follows.
- Example 2 Ten mg of anti-human STS monoclonal antibody KM1053 was coupled to 5 mL of Hi-Trap NHS-activated (Pharmacia Biotech). The same 33-1 cells (about 50 X 107 cells) obtained in Example 2 (3) were statically cultured in a B3 medium in a petri dish. After washing the petri dish with PBS, the cells on the petri dish were collected with a cell scraper.
- TC S buffer 50 mmol / L Tris-HCl buffer (pH 7.8) containing 1% CHAPS, 0.5 mol / L NaCl
- the purified anti-human STS monoclonal antibody KM1053 at a concentration of 10 ⁇ g / mL was dispensed into a 96-well EIA plate at 50 L / well and allowed to stand at 4 ° C for adsorption. After washing, 1% BSA-PBS was added at 100 L / well and reacted at room temperature for 1 hour to block remaining active groups. Discard 1% BSA-PBS, and add 50 ⁇ L / fold of a 2-fold dilution series of purified human STS or control protein (recombinant purified IL-1 ⁇ ) obtained in (2) above from ⁇ ⁇ g / mL. The solution was dispensed in holes and allowed to react overnight at 4 ° C.
- human STS could be quantified by using anti-human STS monoclonal antibody KM1053, and its detection limit concentration was about 0.01 ⁇ g / mL.
- STS human steroid sulfatase
- ARS arylsulfatase other than human STS
- Antibodies or antibody fragments and hybridomas that produce the antibodies are provided.
- a human STS immunological detection method or immunological quantification method, a human STS immunological detection reagent or kit, and an immunological quantification reagent or the like using the antibody or antibody fragment Kits and further, immunology of human STS using the antibody or antibody fragment for determining human STS-related diseases, selecting drugs suitable for treatment of human STS-related diseases, and determining the pathology of human STS-related diseases Detection method or immunological determination method, reagent or kit for immunological detection of human STS and reagent for immunological determination or A kit is provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006546638A JPWO2006059712A1 (ja) | 2004-12-02 | 2005-12-02 | ヒトステロイドサルファターゼに結合するモノクローナル抗体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-350246 | 2004-12-02 | ||
JP2004350246 | 2004-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006059712A1 true WO2006059712A1 (ja) | 2006-06-08 |
Family
ID=36565144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/022169 WO2006059712A1 (ja) | 2004-12-02 | 2005-12-02 | ヒトステロイドサルファターゼに結合するモノクローナル抗体 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2006059712A1 (ja) |
WO (1) | WO2006059712A1 (ja) |
-
2005
- 2005-12-02 WO PCT/JP2005/022169 patent/WO2006059712A1/ja active Application Filing
- 2005-12-02 JP JP2006546638A patent/JPWO2006059712A1/ja active Pending
Non-Patent Citations (4)
Title |
---|
BONIFAS J.M. ET AL: "Cloning of a cDNA for steroid sulfatase: frequent occurrence of gene deletions in patients with recessive X chromosome-linked ichthyosis", PROC NATL ACAD SCI USA, vol. 84, no. 24, December 1987 (1987-12-01), pages 9248 - 9251, XP002995590 * |
SAEKI T. ET AL: "Localization of Estrone Sulfatase in Human Breast Carcinomas", BREAST CANCER, vol. 6, no. 4, 1999, pages 331 - 337, XP002995589 * |
SUZUKI T. ET AL: "Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma", CANCER RES., vol. 63, no. 11, 1 June 2003 (2003-06-01), pages 2762 - 2770, XP002995588 * |
YEN P.H. ET AL: "Cloning and expression of steroid sulfatase cDNA and the frequent occurrence of deletions in STS deficiency: implications for X-Y interchange", CELL, vol. 49, no. 4, 22 May 1987 (1987-05-22), pages 443 - 454, XP002995587 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006059712A1 (ja) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2270509B1 (en) | Method for detection of liver cancer cell using anti-glypican-3 antibody | |
KR101976219B1 (ko) | 유방암의 바이오마커 | |
JP5847755B2 (ja) | 細胞を検出する方法、およびこれに有用な薬剤 | |
CA2813098C (en) | Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e | |
US20180017575A1 (en) | Histone protein ubiquitination as a cancer biomarker | |
US11667711B2 (en) | Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC) | |
US20090023160A1 (en) | Antibodies specific for CYP1B1 | |
Sticova et al. | Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis | |
WO2005052156A1 (ja) | 肝癌の検出方法及び肝癌診断薬並びに癌治療薬 | |
KR20120095301A (ko) | 항-사이토케라틴 8/18 복합체 자가면역항체를 포함하는 암 진단 마커 및 이의 항원을 포함하는 암 진단용 조성물 | |
CN113272332B (zh) | 抗Claudin18.2的抗体及其应用 | |
WO2006059712A1 (ja) | ヒトステロイドサルファターゼに結合するモノクローナル抗体 | |
EP1701166A1 (en) | SP1 as a marker in diagnosis and prognosis of non-alcoholic steatohepatitis (nash) and target in drug screening for nash | |
US20070275420A1 (en) | Method For Detecting Prognosis Of Cancer | |
KR101567053B1 (ko) | 방사선 피폭에 의한 간 손상 예측용 바이오마커 및 그 예측방법 | |
JP2013096783A (ja) | 肺腺癌を判定するためのデータ検出方法、診断薬、及び診断用キット | |
JP4993065B2 (ja) | 肝細胞癌の診断方法 | |
JP2004538452A (ja) | 診断法と診断薬 | |
CN116635718A (zh) | 用于在免疫组织化学(ihc)方案中使用以诊断癌症的抗人cd10抗体 | |
EP3329283B1 (en) | Method for the normalization of immunological tests | |
WO2018034332A1 (ja) | EphA2 N末端フラグメント抗体 | |
WO2008012941A1 (fr) | Méthode de diagnostic d'une insuffisance cardiaque | |
KR20180099722A (ko) | 예측 방법 및 상기 방법에 유용한 키트 | |
KR20180081277A (ko) | P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델 | |
JP2008503718A (ja) | 良性前立腺過形成のマーカーとしてのjm−27 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006546638 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05811645 Country of ref document: EP Kind code of ref document: A1 |